<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="generator" content=
"HTML Tidy for HTML5 for Mac OS X version 5.4.0" />
<title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">
<p style="margin: 0">&nbsp;</p>
<!-- Field: Rule-Page -->
<div align="left" style="margin-top: 0; margin-bottom: 0">
<div style=
"font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">
&nbsp;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0"></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>UNITED STATES</b></p>
<p style=
"font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>WASHINGTON, DC 20549</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>FORM 10-Q</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>(Mark One)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 2%; font-size: 10pt"><font style=
"font-family: Wingdings">x</font></td>
<td style="width: 97%; font-size: 10pt; text-align: justify">
<font style="font-size: 10pt"><b>QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934</b></font></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>For the quarterly period ended March31, 2018</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>or</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<table cellspacing="0" cellpadding="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 1%">&nbsp;</td>
<td style="width: 2%"><font style=
"font-family: Wingdings">¨</font></td>
<td style="width: 97%; text-align: justify"><font style=
"font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>For the transition period from
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>COMMISSION FILE NO. 001-37759</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<p style=
"font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>ONCOBIOLOGICS, INC.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>(EXACT NAME OF REGISTRANT AS SPECIFIEDIN ITS CHARTER)</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
<td style=
"vertical-align: top; width: 50%; padding-left: 3.3pt; text-align: center">
<b>DELAWARE</b></td>
<td style="vertical-align: bottom; width: 1%; padding-left: 3.3pt">
&nbsp;</td>
<td style=
"vertical-align: top; width: 49%; padding-left: 3.3pt; text-align: center">
<b>38-3982704</b></td>
</tr>
<tr style="vertical-align: bottom">
<td>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>(STATE OR OTHER JURISDICTION OF</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>INCORPORATION OR ORGANIZATION)</b></p>
</td>
<td style="padding-left: 3.3pt">&nbsp;</td>
<td>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>(I.R.S. EMPLOYER</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>IDENTIFICATION NO.)</b></p>
</td>
</tr>
<tr style="vertical-align: bottom">
<td style="padding-left: 3.3pt">&nbsp;</td>
<td colspan="2" style="padding-left: 3.3pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>7 CLARKE DRIVE</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>CRANBURY, NEW JERSEY</b></p>
</td>
<td style="padding-left: 3.3pt">&nbsp;</td>
<td style="padding-left: 3.3pt; text-align: center">
<b>08512</b></td>
</tr>
<tr>
<td style=
"vertical-align: top; padding-left: 3.3pt; text-align: center">
<b>(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)</b></td>
<td style="vertical-align: bottom; padding-left: 3.3pt">&nbsp;</td>
<td style=
"vertical-align: top; padding-left: 3.3pt; text-align: center">
<b>(ZIP CODE)</b></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>REGISTRANT’S TELEPHONE NUMBER,INCLUDING AREA CODE:
(609)&nbsp;619-3990</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Indicate by check mark whether the registrant:(1)&nbsp;has filed
all reports required to be filed by Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 during thepreceding 12&nbsp;months
(or for such shorter period that the registrant was required to
file such reports), and (2)&nbsp;has beensubject to such filing
requirements for the past
90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp; <font style=
"font-family: Wingdings">x</font>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
<font style="font-family: Wingdings">¨</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Indicate by check mark whether the registranthas submitted
electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submittedand posted pursuant
to Rule&nbsp;405 of Regulation&nbsp;S-T (§232.405 of this chapter)
during the preceding 12&nbsp;months(or for such shorter period that
the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp; <font style=
"font-family: Wingdings">x</font>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
<font style="font-family: Wingdings">¨</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Indicate by check mark whether the registrantis a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company or an emerging growthcompany. See the definitions
of “large accelerated filer”, “accelerated filer,” “smaller
reportingcompany and emerging growth company” in Rule&nbsp;12b-2 of
the Exchange Act.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 22%">Large&nbsp;accelerated&nbsp;filer</td>
<td style="width: 52%"><font style=
"font-family: Wingdings">¨</font></td>
<td style="width: 21%">Accelerated&nbsp;filer</td>
<td style="width: 5%"><font style=
"font-family: Wingdings">¨</font></td>
</tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td>Non-accelerated filer</td>
<td><font style="font-family: Wingdings">¨</font>&nbsp;&nbsp;(Do
not check if a smaller reporting company)</td>
<td>Smaller&nbsp;reporting&nbsp;company</td>
<td><font style="font-family: Wingdings">x</font></td>
</tr>
<tr style="vertical-align: top">
<td>Emerging growth company</td>
<td><font style="font-family: Wingdings">x</font></td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">
If an emerging growth company, indicateby check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financialaccounting standards
provided pursuant to Section 13(a) of the Exchange Act.
<font style="font-family: Wingdings">x</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Indicate by check mark whether the registrant is a shell company(as
defined in Rule 12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp; &nbsp; <font style=
"font-family: Wingdings">¨</font>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
<font style="font-family: Wingdings">x</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The number of shares of the registrant’s common stock,$0.01 par
value, outstanding as of May 14, 2018 was 32,332,568.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</p>
<!-- Field: Rule-Page -->
<div align="left" style="margin-top: 0; margin-bottom: 0">
<div style=
"font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">
&nbsp;</div>
</div>
<!-- Field: /Rule-Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<!-- Field: Page; Sequence: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 100%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Table of Contents</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="width: 90%">&nbsp;</td>
<td style=
"width: 10%; border-bottom: black 1pt solid; text-align: center; vertical-align: bottom">
<font style="font-size: 10pt"><b>Page</b></font><br />
<font style="font-size: 10pt"><b>Number</b></font></td>
</tr>
<tr style="vertical-align: bottom">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_001" style=
"-sec-extract: exhibit">PART&nbsp;I.&nbsp;FINANCIAL&nbsp;INFORMATION</a></td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_002">Item&nbsp;1. Financial Statements</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_002">1</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_003">Consolidated Balance Sheets as of March 31,
2018 and September 30, 2017</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_003">1</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_004">Consolidated Statements of Operations for the
Three and Six Months Ended March 31, 2018 and 2017</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_004">2</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_005">Consolidated Statement of Convertible
Preferred Stock and Stockholders’ Equity (Deficit) for the Six
Months Ended March 31, 2018</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_005">3</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_006">Consolidated Statements of Cash Flows for the
Six Months Ended March 31, 2018 and 2017</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_006">4</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_007">Notes to Unaudited Interim Consolidated
Financial Statements</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_007">5</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_008">Item&nbsp;2. Management’s Discussion and
Analysis of Financial Condition and Results of Operations</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_008">15</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_009">Item&nbsp;3. Quantitative and Qualitative
Disclosures About Market Risk</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_009">26</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_010">Item&nbsp;4. Controls and Procedures</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_010">27</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_011">PART II. OTHER INFORMATION</a></td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_012">Item&nbsp;1. Legal Proceedings</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_012">27</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_013">Item&nbsp;1A. Risk Factors</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_013">27</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_014">Item&nbsp;2. Unregistered Sales of Equity
Securities and Use of Proceeds</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_014">27</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_015">Item&nbsp;3. Defaults Upon Senior
Securities</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_015">27</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_016">Item&nbsp;4. Mine Safety Disclosures</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_016">27</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_017">Item 5. Other Information</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_017">27</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_018">Item&nbsp;6. Exhibits</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_018">28</a></td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td>&nbsp;</td>
<td style="text-align: right; vertical-align: bottom">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; background-color: rgb(204,238,255)">
<td><a href="#a_019">SIGNATURES</a></td>
<td style="text-align: right; vertical-align: bottom"><a href=
"#a_019">29</a></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">&nbsp;
<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i
<!-- Field: /Sequence --></td>
<td style="width: 33%">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_001" id="a_001"></a>PART I. FINANCIAL
INFORMATION</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_002" id="a_002"></a>Item 1. Financial
Statements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b><a name="a_003" id="a_003"></a>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Consolidated Balance Sheets</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>(unaudited)</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">March 31,</td>
<td style="font-weight: bold">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">September 30,</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: center">Assets</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Current assets:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%; padding-left: 9pt">Cash</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">5,936,115</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">3,185,519</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 9pt">Prepaid
and other current assets</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
981,590</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
719,087</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt">Total current
assets</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">6,917,705</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,904,606</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Property and equipment, net</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">20,176,847</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">16,088,902</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Other assets</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
692,104</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
740,362</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total
assets</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
27,786,656</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
20,733,870</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-weight: bold; text-align: center">Liabilities,
convertible preferred stock and stockholders’ equity (deficit)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Current liabilities:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt">Senior secured
notes</td>
<td>&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">12,507,368</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt">Current portion of
long-term debt</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">102,907</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">52,600</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt">Current portion of
capital lease obligations</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">855,233</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">341,120</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt">Stockholder
notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">4,612,500</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">4,612,500</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt">Accounts
payable</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,607,776</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">10,954,358</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt">Accrued
expenses</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,038,283</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">7,337,469</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt">Income taxes
payable</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,352,129</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,352,129</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 9pt">Deferred
revenue</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,676,103</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
3,087,561</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total
current liabilities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
31,752,299</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
28,737,737</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Senior secured notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">13,231,700</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Long-term debt</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">127,787</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">151,110</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Capital lease obligations</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,510,811</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">28,067</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Warrant liability</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,984,179</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,274,954</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Deferred revenue</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,334,543</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">4,466,865</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Other
liabilities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,347,344</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,569,971</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total
liabilities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
43,056,963</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
51,460,404</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Commitments (Note 8)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">
Series A convertible preferred stock, par value $0.01 per share:
1,000,000 shares authorized, 261,045 and 32,628 shares&nbsp;issued
and outstanding at March 31, 2018 and September 30, 2017,
respectively</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
18,294,782</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,924,441</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; text-indent: -0.1in; padding-left: 0.1in">
Stockholders’ equity (deficit):</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.1in; padding-left: 0.25in">Preferred
stock, par value $0.01 per share: 7,500,000 shares authorized, no
shares issued and outstanding at March 31, 2018 and September 30,
2017, respectively</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; text-indent: -0.1in; padding-left: 0.25in">
Series B convertible preferred stock, par value $0.01 per share:
1,500,000 shares authorized, 1,500,000 and no shares&nbsp;issued
and outstanding at March 31, 2018 and September 30, 2017,
respectively</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,661,972</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.1in; padding-left: 0.25in">Common stock,
par value $0.01 per share; 200,000,000 shares authorized;
25,740,458 and 24,933,944 shares issued and outstanding at March
31, 2018 and September 30, 2017, respectively</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">257,405</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">249,339</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.125in">Additional
paid-in capital</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">159,191,316</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">152,315,088</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.125in">
Accumulated deficit</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(195,675,782</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(186,215,402</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.125in">
Total stockholders' equity (deficit)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(33,565,089</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(33,650,975</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">
Total liabilities, convertible preferred stock and stockholders'
equity (deficit)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
27,786,656</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
20,733,870</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
The accompanying notes are anintegral part of these unaudited
interim consolidated financial statements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">
&nbsp;</p>
<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b><a name="a_004" id="a_004"></a>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Consolidated Statements of Operations</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>(unaudited)</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Three Months Ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Six Months Ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 48%; text-align: left; padding-bottom: 1pt">
Collaboration revenues</td>
<td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
<td style=
"width: 1%; border-bottom: Black 1pt solid; text-align: left">
$</td>
<td style=
"width: 10%; border-bottom: Black 1pt solid; text-align: right">
771,890</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
<td style=
"width: 1%; border-bottom: Black 1pt solid; text-align: left">
$</td>
<td style=
"width: 10%; border-bottom: Black 1pt solid; text-align: right">
303,140</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
<td style=
"width: 1%; border-bottom: Black 1pt solid; text-align: left">
$</td>
<td style=
"width: 10%; border-bottom: Black 1pt solid; text-align: right">
1,543,780</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
<td style=
"width: 1%; border-bottom: Black 1pt solid; text-align: left">
$</td>
<td style=
"width: 10%; border-bottom: Black 1pt solid; text-align: right">
606,281</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Operating expenses:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt">Research and
development</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,156,386</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">4,116,856</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,558,788</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">17,347,243</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 9pt">General
and administrative</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,446,505</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
4,024,276</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
5,995,757</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
8,892,271</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
7,602,891</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
8,141,132</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
11,554,545</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
26,239,514</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Loss from operations</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(6,831,001</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(7,837,992</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(10,010,765</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(25,633,233</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Interest expense, net</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">920,870</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,243,892</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,638,753</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,733,037</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Loss on extinguishement of debt</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,252,353</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Change in fair
value of warrant liability</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(211,992</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(1,035,902</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(290,775</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(225,819</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Loss before income taxes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(7,539,879</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(8,045,982</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(12,611,096</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(27,140,451</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Income tax
(benefit) expense</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(3,150,716</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
4,000</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Net loss</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(7,539,879</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(8,045,982</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(9,460,380</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(27,144,451</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; text-indent: 0in; padding-left: 0in">
Recognition of beneficial conversion feature upon issuance of
Series A convertible preferred stock</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(381,664</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(15,736,683</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Series A
convertible preferred stock dividends and related settlement</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(636,695</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(1,087,496</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 2.5pt">Net loss
attributable to common stockholders</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(8,558,238</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(8,045,982</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(26,284,559</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(27,144,451</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Per share information:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 2.5pt">Net loss per
share of common stock, basic</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(0.33</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(0.34</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(1.04</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(1.16</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 2.5pt">Net loss per
share of common stock, diluted</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(0.34</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(0.38</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(1.05</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(1.16</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 2.5pt">Weighted average shares
outstanding, basic</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
25,733,467</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
23,723,551</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
25,364,247</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
23,457,361</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt">Weighted average shares
outstanding, diluted</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
25,733,467</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
23,801,223</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
25,364,247</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
23,496,197</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
The accompanying notes are an integral partof these unaudited
interim consolidated financial statements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<!-- Field: Page; Sequence: 4; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b><a name="a_005" id="a_005"></a>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Consolidated Statements of ConvertiblePreferred Stock and
Stockholders’ Equity (Deficit)</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Six Months Ended March 31, 2018</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>(unaudited)</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 8pt">
<td nowrap="nowrap" style="text-align: center; font-size: 8pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Convertible Preferred Stock</td>
<td style=
"padding-bottom: 1pt; font-weight: bold; font-size: 8pt; border-right: Black 1pt solid">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="26" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Stockholders' Equity (Deficit)</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; font-size: 8pt">
<td nowrap="nowrap" style="font-size: 8pt">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Series A</td>
<td style=
"padding-bottom: 1pt; font-weight: bold; font-size: 8pt; border-right: Black 1pt solid">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Series B Convertible<br style="font-size: 8pt" />
Preferred Stock</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Common Stock</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; padding-bottom: 1pt; font-size: 8pt">
Additional Paid-in</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; padding-bottom: 1pt; font-size: 8pt">
Accumulated</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; padding-bottom: 1pt; font-size: 8pt">
Total Stockholders'</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; font-size: 8pt">
<td nowrap="nowrap" style="text-align: center; font-size: 8pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Shares</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Amount</td>
<td style=
"padding-bottom: 1pt; font-weight: bold; font-size: 8pt; border-right: Black 1pt solid">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Shares</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Amount</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Shares</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Amount</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Capital</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Deficit</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">
Equity (Deficit)</td>
<td style="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255); font-size: 8pt">
<td style="width: 28%; font-size: 8pt">Balance at October 1,
2017</td>
<td style="width: 1%; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; text-align: left; font-size: 8pt">&nbsp;</td>
<td style="width: 5%; text-align: right; font-size: 8pt">
32,628</td>
<td style="width: 1%; text-align: left; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; text-align: left; font-size: 8pt">$</td>
<td style="width: 5%; text-align: right; font-size: 8pt">
2,924,441</td>
<td style=
"width: 1%; text-align: left; font-size: 8pt; border-right: Black 1pt solid">
&nbsp;</td>
<td style="width: 1%; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; text-align: left; font-size: 8pt">&nbsp;</td>
<td style="width: 5%; text-align: right; font-size: 8pt">-</td>
<td style="width: 1%; text-align: left; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; text-align: left; font-size: 8pt">$</td>
<td style="width: 5%; text-align: right; font-size: 8pt">-</td>
<td style="width: 1%; text-align: left; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; text-align: left; font-size: 8pt">&nbsp;</td>
<td style="width: 5%; text-align: right; font-size: 8pt">
24,933,944</td>
<td style="width: 1%; text-align: left; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; text-align: left; font-size: 8pt">$</td>
<td style="width: 5%; text-align: right; font-size: 8pt">
249,339</td>
<td style="width: 1%; text-align: left; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; text-align: left; font-size: 8pt">$</td>
<td style="width: 5%; text-align: right; font-size: 8pt">
152,315,088</td>
<td style="width: 1%; text-align: left; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; text-align: left; font-size: 8pt">$</td>
<td style="width: 5%; text-align: right; font-size: 8pt">
(186,215,402</td>
<td style="width: 1%; text-align: left; font-size: 8pt">)</td>
<td style="width: 1%; font-size: 8pt">&nbsp;</td>
<td style="width: 1%; text-align: left; font-size: 8pt">$</td>
<td style="width: 5%; text-align: right; font-size: 8pt">
(33,650,975</td>
<td style="width: 1%; text-align: left; font-size: 8pt">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: White; font-size: 8pt">
<td style="text-align: left; font-size: 8pt">Issuance of vested
restricted stock units</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style=
"text-align: left; font-size: 8pt; border-right: Black 1pt solid">
&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">806,514</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">8,066</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">(8,066</td>
<td style="text-align: left; font-size: 8pt">)</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255); font-size: 8pt">
<td style="text-align: left; font-size: 8pt">Sale of Series A
convertible preferred stock and common stock warrants, net of
costs</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">217,372</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">14,265,861</td>
<td style=
"text-align: left; font-size: 8pt; border-right: Black 1pt solid">
&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">6,382,181</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">6,382,181</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: White; font-size: 8pt">
<td style="text-align: left; font-size: 8pt">Series A convertible
preferred stock dividends and settlement</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">11,045</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">1,104,480</td>
<td style=
"text-align: left; font-size: 8pt; border-right: Black 1pt solid">
&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">(1,087,496</td>
<td style="text-align: left; font-size: 8pt">)</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">(1,087,496</td>
<td style="text-align: left; font-size: 8pt">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255); font-size: 8pt">
<td style="text-align: left; font-size: 8pt">Conversion of senior
secured notes into Series B convertible preferred stock</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style=
"text-align: left; font-size: 8pt; border-right: Black 1pt solid">
&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">1,500,000</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">2,661,972</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">2,661,972</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: White; font-size: 8pt">
<td style="text-align: left; font-size: 8pt">Stock-based
compensation expense</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style=
"text-align: left; font-size: 8pt; border-right: Black 1pt solid">
&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">1,589,609</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">-</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="font-size: 8pt">&nbsp;</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
<td style="text-align: right; font-size: 8pt">1,589,609</td>
<td style="text-align: left; font-size: 8pt">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255); font-size: 8pt">
<td style="text-align: left; padding-bottom: 1pt; font-size: 8pt">
Net loss</td>
<td style="padding-bottom: 1pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">
-</td>
<td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style="padding-bottom: 1pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">
-</td>
<td style=
"padding-bottom: 1pt; text-align: left; font-size: 8pt; border-right: Black 1pt solid">
&nbsp;</td>
<td style="padding-bottom: 1pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">
-</td>
<td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style="padding-bottom: 1pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">
-</td>
<td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style="padding-bottom: 1pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">
-</td>
<td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style="padding-bottom: 1pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">
-</td>
<td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style="padding-bottom: 1pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">
-</td>
<td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style="padding-bottom: 1pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">
(9,460,380</td>
<td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">
)</td>
<td style="padding-bottom: 1pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">
(9,460,380</td>
<td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">
)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: White; font-size: 8pt">
<td style="padding-bottom: 2.5pt; font-size: 8pt">Balance at March
31, 2018</td>
<td style="padding-bottom: 2.5pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">
261,045</td>
<td style=
"padding-bottom: 2.5pt; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style="padding-bottom: 2.5pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">
$</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">
18,294,782</td>
<td style=
"padding-bottom: 2.5pt; text-align: left; font-size: 8pt; border-right: Black 1pt solid">
&nbsp;</td>
<td style="padding-bottom: 2.5pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">
1,500,000</td>
<td style=
"padding-bottom: 2.5pt; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style="padding-bottom: 2.5pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">
$</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">
2,661,972</td>
<td style=
"padding-bottom: 2.5pt; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style="padding-bottom: 2.5pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">
25,740,458</td>
<td style=
"padding-bottom: 2.5pt; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style="padding-bottom: 2.5pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">
$</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">
257,405</td>
<td style=
"padding-bottom: 2.5pt; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style="padding-bottom: 2.5pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">
$</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">
159,191,316</td>
<td style=
"padding-bottom: 2.5pt; text-align: left; font-size: 8pt">
&nbsp;</td>
<td style="padding-bottom: 2.5pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">
$</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">
(195,675,782</td>
<td style=
"padding-bottom: 2.5pt; text-align: left; font-size: 8pt">)</td>
<td style="padding-bottom: 2.5pt; font-size: 8pt">&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">
$</td>
<td style=
"border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">
(33,565,089</td>
<td style=
"padding-bottom: 2.5pt; text-align: left; font-size: 8pt">)</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
The accompanying notes are an integral partof these unaudited
interim consolidated financial statements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<!-- Field: Page; Sequence: 5; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b><a name="a_006" id="a_006"></a>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Consolidated Statements of Cash Flows</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>(unaudited)</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Six Months Ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left">OPERATING
ACTIVITIES</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 74%; text-align: left; padding-left: 9pt">Net
loss</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">(9,460,380</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">(27,144,451</td>
<td style="width: 1%; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt">Adjustments to
reconcile net loss to net cash used in operating activities:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 0.25in">Depreciation and
amortization</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,407,888</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,349,930</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.25in">Loss on
extinguishment of debt</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,252,353</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 0.25in">Non-cash
interest expense</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">970,287</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">977,693</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.25in">Stock-based
compensation</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,589,609</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">4,791,443</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 0.25in">Change in fair
value of warrant liability</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(290,775</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(225,819</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 0.25in">Changes in
operating assets and liabilities:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 27pt">Prepaid expenses
and other current assets</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(262,503</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,552,975</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 27pt">Other assets</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(56,401</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">33,550</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 27pt">Accounts
payable</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(6,909,512</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">6,973,453</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 27pt">Accrued
expenses</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(2,584,186</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,193,392</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 27pt">Deferred
revenue</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(1,543,780</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(606,280</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 27pt">Other
liabilities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(222,627</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
151,986</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 9pt">Net cash
used in operating activities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(16,110,027</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(9,952,128</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-weight: bold; text-align: left">INVESTING
ACTIVITIES</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 9pt">Purchase
of property and equipment</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(1,350,329</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(191,877</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 9pt">Net cash
used in investing activities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(1,350,329</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(191,877</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left">FINANCING
ACTIVITIES</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt">Proceeds from the
sale of common stock, net of offering costs</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">679,789</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt">Payment of debt
issuance costs</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(40,000</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt">Proceeds from
issuance of Series A convertible preferred stock</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">21,737,200</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt">Proceeds from the
sale of senior secured notes and detachable warrants</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">10,000,000</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt">Proceeds from
exercise of common stock warrants</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">123,001</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt">Change in
restricted cash</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">216,086</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt">Payments of capital
leases obligations</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(375,081</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(477,299</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 9pt">Repayment of debt</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(62,009</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(2,628,410</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 9pt">Payment
of financing costs</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(1,089,158</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net
cash provided by financing activities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
20,210,952</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
7,873,167</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Net increase (decrease) in cash</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,750,596</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(2,270,838</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1pt">Cash at beginning of period</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
3,185,519</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,351,887</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt">Cash at end of period</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
5,936,115</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
81,049</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Supplemental disclosure of cash flow
information</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 2.5pt">Cash paid for
interest</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
25,505</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
418,496</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Supplemental schedule of noncash
investing activities:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">
Purchases of property and equipment in accounts payable and accrued
expenses</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
27,870</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
79,236</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Supplemental schedule of noncash
financing activities:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">
Issuance of Series B convertible preferred stock upon conversion of
senior secured notes, net of unamortized debt discount</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
1,409,619</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
-</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">
Issuance of capital lease obligations in connection with purchase
of property and equipment</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
3,401,964</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
62,230</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Series
A convertible preferred stock dividends</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
-</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
-</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">
Settlement of Series A convertible preferred stock dividends upon
issuance of Series A convertible preferred stock</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
1,104,480</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
-</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">
Deferred offering costs and common stock issuance costs in accounts
payable and accrued expenses</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
-</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(288,725</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
The accompanying notes are an integral partof these unaudited
interim consolidated financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 6; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Notes to Unaudited Interim Consolidated
FinancialStatements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><a name="a_007" id="a_007"></a>1.&nbsp;&nbsp;&nbsp;Organization
and Description of Business</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Oncobiologics, Inc. (“Oncobiologics”or the “Company”) was
incorporated in New Jersey on January 5, 2010 and started
operations in July 2011. Oncobiologicsis a clinical-stage
biopharmaceutical company focused on identifying, developing,
manufacturing and commercializing complex monoclonalantibody (“mAb”
) therapeutics. The Company has established fully integrated
in-house development and manufacturingcapabilities that addresses
the numerous complex technical and regulatory challenges in
developing and commercializing mAb therapeutics.Since inception,
the Company has advanced two product candidates through Phase 1
clinical trials: ONS-3010, a biosimilar to adalimumab(Humira®) and
ONS-1045, a biosimilar to bevacizumab (Avastin®). Additionally, the
Company has a pipeline of preclinicalproduct candidates in various
stages of development. The Company is based in Cranbury, New
Jersey.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>2.&nbsp;&nbsp;&nbsp;Liquidity</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company has incurred substantial lossesand negative cash flows
from operations since its inception and has an accumulated deficit
of $195.7&nbsp;million as ofMarch 31, 2018. The Company has
substantial indebtedness that includes $13.5&nbsp;million of senior
secured notes due in December&nbsp;2018and $4.6&nbsp;million in
notes payable to stockholders that are payable on demand. There can
be no assurance that the holders ofthe stockholder notes will not
exercise their right to demand repayment. These factors raise
substantial doubt about the Company’sability to continue as a going
concern. The accompanying unaudited interim consolidated financial
statements have been preparedon a going concern basis, which
contemplates the realization of assets and satisfaction of
liabilities in the normal course ofbusiness. The unaudited interim
consolidated financial statements do not include any adjustments
related to the recoverabilityand classification of recorded asset
amounts or the amounts and classification of liabilities that might
result from the outcomeof this uncertainty.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Management believes thatthe Company’s existing cash as of March 31,
2018 and the proceeds received and to be received fromthe May 2018
private placement of common stock and warrants, will be sufficient
to fund its operations throughDecember 2018, excluding repayment of
debt. See Note 11. Substantial additional financing will be needed
by the Companyto fund its operations in the future and to
commercially develop its product candidates. Management is
currently evaluatingdifferent strategies to obtain the required
funding for future operations. These strategies may include, but
are not limitedto: private placements of equity and/or debt,
payments from potential strategic research and development,
licensingand/or marketing arrangements with pharmaceutical
companies, providing manufacturing services on a contract basis
toother biopharmaceutical companies and public offerings of equity
and/or debt securities. There can be no assurance thatthese future
funding efforts will be successful.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company’s future operations arehighly dependent on a
combination of factors, including (i) the timely and successful
completion of additional financing discussedabove; (ii) the Company’
s ability to complete revenue-generating partnerships with
pharmaceutical companies; (iii) the successof its research and
development; (iv) the development of competitive therapies by other
biotechnology and pharmaceutical companies,and, ultimately, (v)
regulatory approval and market acceptance of the Company’s proposed
future products.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b><font style="color: #231F20">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>3.&nbsp;&nbsp;&nbsp;Basis of Presentation and Summary
ofSignificant Accounting Policies</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Basis of presentation</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The accompanying unaudited interim consolidatedfinancial statements
have been prepared in conformity with U.S. generally accepted
accounting principles (“GAAP”) forinterim financial information.
Any reference in these notes to applicable guidance is meant to
refer to GAAP as found in the AccountingStandards Codification (
“ASC”) and Accounting Standards Updates (“ASU”) of the Financial
Accounting StandardsBoard (“FASB”).</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In the opinion of management, the accompanyingunaudited interim
consolidated financial statements include all normal and recurring
adjustments (which consist primarily of accruals,estimates and
assumptions that impact the financial statements) considered
necessary to present fairly the Company’s financialposition as of
March 31, 2018 and its results of operations for the three and six
months ended March 31, 2018 and 2017 and cashflows for the six
months ended March 31, 2018. Operating results for the three and
six months ended March 31, 2018 are not necessarilyindicative of
the results that may be expected for the full year ending September
30, 2018. The unaudited interim consolidatedfinancial statements,
presented herein, do not contain the required disclosures under
GAAP for annual consolidated financial statements.The accompanying
unaudited interim consolidated financial statements should be read
in conjunction with the annual audited consolidatedfinancial
statements and related notes as of and for the year ended September
30, 2017 included in the Company’s Annual Reporton Form 10-K, as
amended to date, filed with the Securities and Exchange Commission
(“SEC”), on December 29, 2017.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>&nbsp;</b></p>
<!-- Field: Page; Sequence: 7; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Notes to Unaudited Interim Consolidated
FinancialStatements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Use of estimates</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The preparation of the unaudited interimconsolidated financial
statements in conformity with GAAP requires management to make
estimates and assumptions that affect thereported amounts of assets
and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statementsand reported amounts of
revenues and expenses during the reporting period. Actual results
could differ from those estimates. Dueto the uncertainty of factors
surrounding the estimates or judgments used in the preparation of
the unaudited interim consolidatedfinancial statements, actual
results may materially vary from these estimates. Estimates and
assumptions are periodically reviewedand the effects of revisions
are reflected in the unaudited interim consolidated financial
statements in the period they are determinedto be necessary.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Income taxes</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In November 2017, the Company receivedapproval from the New Jersey
Economic Development Authority’s Technology Business Tax
Certificate Transfer Program to sella portion of its unused New
Jersey net operating losses (“NOLs”), and research and development
(“R&amp;D”)tax credits. As a result, the Company received $3.15
million of cash from the sale of these NOLs and credits in December
2017,which it recognized as an income tax benefit for the six
months ended March 31, 2018. The Company recorded income tax
expense of$4,000 for the six months ended March 31, 2017, which is
primarily attributable to state and foreign withholding taxes in
connectionwith the Company’s collaboration and licensing
agreements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Net loss per share</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Basic and diluted net loss per common shareis determined by
dividing net loss applicable to common stockholders by the
weighted-average common shares outstanding during theperiod.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
For purposes of calculating diluted lossper common share, the
denominator includes both the weighted average common shares
outstanding and the number of common stock equivalentsif the
inclusion of such common stock equivalents would be dilutive.
Dilutive common stock equivalents potentially include
warrants,stock options and non-vested restricted stock unit (“RSU”)
awards using the treasury stock method. The diluted lossper common
share calculation is further affected by an add-back of change in
fair value of warrant liability to the numerator underthe
assumption that the change in fair value of warrant liability would
not have been incurred if the warrants had been convertedinto
common stock.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The following table sets forth the computationof basic earnings per
share and diluted earnings per share:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Three months ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Six months ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold">Basic Earnings Per Share</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 48%; text-align: left">Net loss</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">(8,558,238</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">(8,045,982</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">(26,284,559</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">(27,144,451</td>
<td style="width: 1%; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 1pt">Common stock outstanding (weighted
average)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
25,733,467</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
23,723,551</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
25,364,247</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
23,457,361</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 2.5pt">Basic net loss per share</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(0.33</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(0.34</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(1.04</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(1.16</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold">Diluted Earnings Per Share</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Net loss</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(8,558,238</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(8,045,982</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(26,284,559</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(27,144,451</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Add change in
fair value of warrant liability</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(211,992</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(1,035,902</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(290,775</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(225,819</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Diluted net loss</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(8,770,230</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(9,081,884</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(26,575,334</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(27,370,270</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>Common stock outstanding (weighted average)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">25,733,467</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">23,723,551</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">25,364,247</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">23,457,361</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Add shares from
dilutive warrants</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
77,672</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
38,836</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Common stock
equivalents</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
25,733,467</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
23,801,223</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
25,364,247</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
23,496,197</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt">Diluted net loss per share</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(0.34</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(0.38</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(1.05</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(1.16</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<!-- Field: Page; Sequence: 8; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Notes to Unaudited Interim Consolidated
FinancialStatements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The following potentially dilutive securitieshave been excluded
from the computation of diluted weighted-average shares outstanding
as of March 31, 2018 and 2017, as they wouldbe antidilutive:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
As of March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%; text-align: left">Series A convertible
preferred stock</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 10%; text-align: right">39,465,772</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 10%; text-align: right">-</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Series B convertible preferred
stock</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,112,676</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Performance-based stock units</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">163,934</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">241,573</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Restricted stock units</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">97,773</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,200,529</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Common stock warrants</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">28,116,505</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">7,786,573</td>
<td style="text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Correction of immaterial error related to prior periods</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
During fiscal 2017, the Company identifiedan error related to its
accounting and classification for the 82,000 square feet of office
and laboratory space in Cranbury, NewJersey that was entered into
during August&nbsp;2015. Due to the Company’s involvement in the
construction required to completethe leased facility, the Company
concluded that the lease should have been accounted for as a direct
financing arrangement, wherebythe Company records, the fair value
of the asset in property and equipment, net on the consolidated
balance sheets. A correspondingliability is also recorded and
amortized over the lease term through monthly rental payments using
the effective interest method.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
For the three and six months ended March31, 2017, rent expense was
overstated by $0.1 million and $0.2 million, respectively, and
interest expense was understated by $0.1&nbsp;millionand $0.2
million, respectively. This was primarily attributable to the
reclassification of rental payments into interest expensepayments
in connection with a financing arrangement rather than an operating
lease arrangement, as previously presented.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company reviewed the impact of thiserror on the prior periods
in accordance with SEC <i>Staff Accounting Bulletin No. 99</i>, <i>
“Materiality,”</i> anddetermined that the error was not material to
the prior periods. However, the Company has corrected the unaudited
interim consolidatedstatement of operations for the three months
ended March 31, 2017 by decreasing research and development
expenses and general andadministrative expenses by $82,000 and
$21,000, respectively, and by increasing interest expense by $0.1
million. The Company correctedthe unaudited interim consolidated
statement of operations for the six months ended March 31, 2017 by
decreasing research and developmentexpenses and general and
administrative expenses by $0.2 million and $42,000, respectively,
and by increasing interest expenseby $0.2 million.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Recently issued and adopted accounting pronouncements</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In May&nbsp;2017, the FASB, issued ASU,No. 2017-09<i>, Compensation 
— Stock Compensation</i>&nbsp;<i>(Topic 718): Scope of Modification
Accounting</i>.This new ASU is intended to provide clarity and
reduce both the diversity in practice of and cost and complexity of
applyingthe guidance in Topic 718,&nbsp;<i>Compensation — Stock
Compensation</i>, to a change to the terms or conditionsof a
share-based payment award. This ASU provides guidance about which
changes to the terms or conditions of a share-based paymentaward
require an entity to apply modification accounting in Topic 718.
This ASU is effective for all entities for annual periods,and
interim periods within those annual periods, beginning after
December&nbsp;15, 2017. Early adoption is permitted. This ASUis not
expected to have a material impact on the Company’s consolidated
financial statements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In February&nbsp;2016, the FASB issuedASU No.
2016-02,&nbsp;<i>Leases</i>, (Topic 842). This new ASU represents a
wholesale change to lease accounting and introducesa lease model
that brings most leases on the balance sheet. It also eliminates
the required use of bright-line tests in currentU.S. GAAP for
determining lease classification. This ASU is effective for annual
periods beginning after December&nbsp;15, 2018(i.e., calendar
periods beginning on January&nbsp;1, 2019), and interim periods
thereafter. Earlier application is permitted forall entities. The
Company is currently evaluating the impact of ASU 2016-02 on its
consolidated financial statements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<!-- Field: Page; Sequence: 9; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Notes to Unaudited Interim Consolidated
FinancialStatements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In May&nbsp;2014, the FASB issued ASU No.2014-09,&nbsp;<i>Revenue
from Contracts with Customers</i>. This guidance requires an entity
to recognize revenue to depict thetransfer of promised goods or
services to customers in an amount that reflects the consideration
to which the entity expects tobe entitled in exchange for those
goods or services. This guidance also requires an entity to
disclose sufficient information toenable users of financial
statements to understand the nature, amount, timing and uncertainty
of revenue and cash flows arisingfrom contracts with customers.
Qualitative and quantitative information is required about:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify"><i>Contracts with customers</i> — 
including revenue and impairments recognized,disaggregation of
revenue and information about contract balances and performance
obligations (including the transaction priceallocated to the
remaining performance obligations).</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify"><i>Significant judgments and
changes in judgments</i> — determining the timingof satisfaction of
performance obligations (over time or at a point in time), and
determining the transaction price and amountsallocated to
performance obligations.</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify"><i>Certain assets</i> — assets
recognized from the costs to obtain or fulfilla contract.</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
​</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In July&nbsp;2015, the FASB delayed theeffective date of this
guidance. As a result, this guidance will be effective for annual
reporting periods beginning after December&nbsp;15,2017, including
interim periods within that reporting period. Earlier application
is permitted only as of annual reporting periodsbeginning after
December&nbsp;15, 2016, including interim reporting periods within
that reporting period. The Company is currentlyevaluating the
impact that this guidance will have on its consolidated results of
operations, financial position and cash flows.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>4.&nbsp;&nbsp;&nbsp;Fair Value Measurements</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Certain assets and liabilities are carriedat fair value under GAAP.
Fair value is defined as the exchange price that would be received
for an asset or paid to transfer aliability (an exit price) in the
principal or most advantageous market for the asset or liability in
an orderly transaction betweenmarket participants on the
measurement date. Valuation techniques used to measure fair value
must maximize the use of observableinputs and minimize the use of
unobservable inputs. Financial assets and liabilities carried at
fair value are to be classifiedand disclosed in one of the
following three levels of the fair value hierarchy, of which the
first two are considered observableand the last is considered
unobservable:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; text-align: justify">
<td style="width: 1%"></td>
<td style="width: 6%; text-align: left">■</td>
<td style="text-align: justify; width: 93%">Level 1 - Quoted prices
in active markets for identicalassets or liabilities.</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.5pt; text-align: justify; text-indent: -13.2pt">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 1%">&nbsp;</td>
<td style="width: 6%">■</td>
<td style="width: 93%; text-align: justify">Level 2 - Observable
inputs (other than Level 1 quoted prices), such as quoted prices in
active markets for similar assets or liabilities, quoted prices in
markets that are not active for identical or similar assets or
liabilities, or other inputs that are observable or can be
corroborated by observable market data.</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.5pt; text-align: justify; text-indent: -13.2pt">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 1%">&nbsp;</td>
<td style="width: 6%">■</td>
<td style="width: 93%; text-align: justify">Level 3 - Unobservable
inputs that are supported by little or no market activity and that
are significant to determining the fair value of the assets or
liabilities, including pricing models, discounted cash flow
methodologies and similar techniques.</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The asset’s or liability’sfair value measurement level within the
fair value hierarchy is based on the lowest level of any input that
is significant to thefair value measurement. Valuation techniques
used need to maximize the use of observable inputs and minimize the
use of unobservableinputs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The following table presents the Company’s assets andliabilities
that are measured at fair value on a recurring basis:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="10" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
March 31,&nbsp;2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
(Level&nbsp;1)</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
(Level&nbsp;2)</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
(Level&nbsp;3)</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold">Liabilities</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 61%; text-align: left">Warrant liability</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">-</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">-</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">1,984,179</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="10" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
September 30,&nbsp;2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
(Level&nbsp;1)</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
(Level&nbsp;2)</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
(Level&nbsp;3)</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold">Liabilities</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 61%; text-align: left">Warrant liability</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">-</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">-</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">2,274,954</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 10; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Notes to Unaudited Interim Consolidated
FinancialStatements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The table presented below is a summary of changes in the fairvalue
of the Company’s Level 3 valuation for the warrant liability for
the six months ended March 31, 2018:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 85%">Balance at October 1, 2017</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">2,274,954</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Change in fair
value</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(290,775</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt">Balance at March 31, 2018</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
1,984,179</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The warrants issued in connection withthe senior secured notes are
classified as liabilities on the accompanying consolidated balance
sheet as such warrants includecash settlement features at the
option of the holders under certain circumstances. The warrant
liability is revalued each reportingperiod with the change in fair
value recorded in the accompanying consolidated statements of
operations until the warrants areexercised or expire. The fair
value of the warrant liability is estimated using the Black-
Scholes option pricing model using thefollowing assumptions:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">March 31,</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 85%; text-align: left">Risk-free interest
rate</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 12%; text-align: center">2.48%</td>
<td style="width: 1%; text-align: left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Remaining contractual life of
warrant</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: center">3.89 years</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Expected volatility</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: center">114%</td>
<td style="text-align: left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Annual dividend yield</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: center">0%</td>
<td style="text-align: left"></td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Fair value of common stock</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: center">$0.89 per share</td>
<td style="text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>5.&nbsp;&nbsp;&nbsp;Property and Equipment, Net</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Property and equipment, net, consists of:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">March 31,</td>
<td style="font-weight: bold">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">September&nbsp;30,</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 70%; text-align: left">Laboratory equipment</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">13,846,649</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">11,574,474</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Leasehold improvements</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">10,032,640</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">10,032,640</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Computer software and hardware</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">483,807</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">472,054</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Land and building</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,000,000</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Construction in
progress</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,866,581</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,654,675</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">30,229,677</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">24,733,843</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Less: accumulated
depreciation and amortization</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(10,052,830</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(8,644,941</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
20,176,847</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
16,088,902</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Depreciation and amortization expense was$706,264 and $680,149 for
the three months ended March 31, 2018 and 2017 respectively, and
$1,407,888 and $1,349,930 for the sixmonths ended March 31, 2018
and 2017, respectively.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
At March 31,2018, $6,965,545 represents laboratory equipment under
capital leases and the Company’s corporate officethat is classified
as a capital lease. At September 30, 2017, $3,692,913 represents
laboratory equipment under capitalleases. The term of the equipment
leases are between 22 and 36 months and qualify as capital leases.
The Company’scorporate office lease matures in February 2028. The
equipment leases bear interest between 5.0% and 19.4% and
theeffective interest rate on the corporate office lease is 43.9%.
At March 31, 2018 and September 30, 2017,$1,259,136 and $1,061,901,
respectively, of accumulated amortization related to capital
leases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<!-- Field: Page; Sequence: 11; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Notes to Unaudited Interim Consolidated
FinancialStatements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>6.&nbsp;&nbsp;&nbsp;Accrued Expenses</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Accrued expenses consists of:</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">March 31,</td>
<td style="font-weight: bold">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">September&nbsp;30,</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 70%">Compensation</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">3,301,826</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">3,688,592</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Research and development</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">125,208</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,637,657</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Interest payable</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,498,560</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,047,122</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Professional fees</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">53,786</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">521,973</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Director fees</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">58,903</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">376,695</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Other accrued
expenses</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
65,430</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
5,038,283</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
7,337,469</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>7.&nbsp;&nbsp;&nbsp;Senior Secured Notes</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">March 31,</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 85%; text-align: left">Senior secured notes</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">13,500,000</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Unamortized debt
discount</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(992,632</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
12,507,368</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In September 2017, the Company enteredinto a purchase and exchange
agreement (the “Exchange Agreement”) with two existing investors
and holders of its seniorsecured notes (the “Noteholders”),
pursuant to which the Noteholders exchanged $1.5&nbsp;million
aggregate principalamount of senior secured notes for 1,500,000
shares of Series&nbsp;B convertible preferred stock (“Series B
Convertible”)and $41,507 of accrued interest on such exchanged
senior secured notes in October 2017. The Company recognized a loss
on extinguishmentof $1,252,353 in connection with the exchange and
represents the excess fair value of the Series B convertible
preferred stockissued over the net carrying amount of the debt and
accrued interest.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Interest expense on the senior securednotes for the three months
ended March 31, 2018 and 2017 was $484,746 and $958,037,
respectively, and $989,331 and $1,047,929 forthe six months ended
March 31, 2018 and 2017, respectively.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>8. &nbsp;&nbsp; Commitments</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
During thethree months ended March 31, 2018, the Company entered
into an amendment to its lease for its corporate offices in
Cranbury,New Jersey. Pursuant to the amended terms, the Company is
occupying 100% of the corporate facility and has extended thelease
term through February 2028 with two five year renewal options. As a
result of this amendment, the lease is nowclassified as a capital
lease. The Company initially recorded the lease obligation and
corresponding building asset based onits estimated fair value of
approximately $3,000,000. The building is being depreciated over
the lease term. Future leasepayments will be allocated to interest
expense and a paydown of the lease obligation.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Future minimum payments under the amendedlease at March 31, 2018
are as follows:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"color: black; font-weight: bold; text-align: center">March
31,</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="color: black; font-weight: bold; padding-bottom: 1pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; color: black; font-weight: bold">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 85%; color: black; text-align: left">Within one
year</td>
<td style="width: 1%; color: black">&nbsp;</td>
<td style="width: 1%; color: black; text-align: left">$</td>
<td style="width: 12%; color: black; text-align: right">
1,491,022</td>
<td style="width: 1%; color: black; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="color: black; text-align: left">Two years</td>
<td style="color: black">&nbsp;</td>
<td style="color: black; text-align: left">&nbsp;</td>
<td style="color: black; text-align: right">1,395,842</td>
<td style="color: black; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="color: black">Three years</td>
<td style="color: black">&nbsp;</td>
<td style="color: black; text-align: left">&nbsp;</td>
<td style="color: black; text-align: right">1,411,752</td>
<td style="color: black; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="color: black; text-align: left">Four years</td>
<td style="color: black">&nbsp;</td>
<td style="color: black; text-align: left">&nbsp;</td>
<td style="color: black; text-align: right">1,486,125</td>
<td style="color: black; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="color: black; text-align: left">Five years</td>
<td style="color: black">&nbsp;</td>
<td style="color: black; text-align: left">&nbsp;</td>
<td style="color: black; text-align: right">1,512,586</td>
<td style="color: black; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="color: black; padding-bottom: 1pt">Thereafter</td>
<td style="color: black; padding-bottom: 1pt">&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; color: black; text-align: left">
&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; color: black; text-align: right">
8,071,794</td>
<td style="padding-bottom: 1pt; color: black; text-align: left">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="color: black; text-align: left; padding-left: 0.125in">
Total rental payments</td>
<td style="color: black">&nbsp;</td>
<td style="color: black; text-align: left">$</td>
<td style="color: black; text-align: right">15,369,121</td>
<td style="color: black; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="color: black; text-align: left; padding-bottom: 1pt">
Less: amount representing interest</td>
<td style="color: black; padding-bottom: 1pt">&nbsp;</td>
<td style=
"color: black; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"color: black; text-align: right; border-bottom: Black 1pt solid">
(12,162,295</td>
<td style="color: black; text-align: left; padding-bottom: 1pt">
)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="color: black; text-align: left; padding-bottom: 2.5pt">
Present value of payments</td>
<td style="color: black; padding-bottom: 2.5pt">&nbsp;</td>
<td style=
"color: black; text-align: left; border-bottom: Black 2.5pt double">
$</td>
<td style=
"color: black; text-align: right; border-bottom: Black 2.5pt double">
3,206,826</td>
<td style="color: black; text-align: left; padding-bottom: 2.5pt">
&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">
&nbsp;</p>
<!-- Field: Page; Sequence: 12; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Notes to Unaudited Interim Consolidated
FinancialStatements</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>9. &nbsp;&nbsp; Convertible PreferredStock and Stockholders’
Equity (Deficit)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
<b>Common stock</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
During the six monthsended March 31, 2018, the Company issued
806,514 shares of common stock upon the vesting of RSUs.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Convertible preferred stock</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In September 2017, the Company enteredinto a purchase agreement
(the “Purchase Agreement”) with GMS Tenshi Holdings Pte. Limited, a
Singapore private limitedcompany (“GMS Tenshi”), pursuant to which
GMS Tenshi agreed to purchase, in a private placement (the 
“PrivatePlacement”), $25.0 million of the Company’s newly-created
voting Series A Convertible Preferred Stock (the “SeriesA
Convertible”), and warrants (the “GMS Tenshi Warrants” and together
with the Series A Convertible, the “Securities”)to acquire
16,750,000 shares of common stock. On September 11, 2017, the
Company completed the initial sale of 32,628 shares ofSeries A
Convertible to GMS Tenshi for $3,262,800 in cash. In October 2017,
the Company completed the sale of the remaining 217,372shares of
Series A Convertible and the GMS Tenshi Warrants to GMS Tenshi in
the Private Placement, for $21,737,200 in cash.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Series&nbsp;A Convertible is initiallyconvertible into
37,795,948 shares of the Company’s common stock, representing an
effective conversion rate of $0.66per share, which represents a
discount to the market value of the Company’s common stock as of
September&nbsp;7, 2017 andOctober 31, 2017 (on which dates, the
closing price of the Company’s common stock was $0.90 and $1.26 per
share, respectively).In connection with the second closing of the
Series&nbsp;A Convertible in October 2017, the Company issued the
GMS Tenshi Warrants,which have a term of 8-years and an initial
exercise price of $0.90 per share. The proceeds from the second
closing of theSeries A Convertible were allocated among the Series
A Convertible and the GMS Tenshi Warrants based on their relative
fair values.As a result of the discount to the market value and the
allocation of a portion of the proceeds to the GMS Tenshi Warrants,
theCompany recognized a beneficial conversion charge of 
$15,355,019, which represents the in-the-money value of the
conversionrate as of the date of sale.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Series&nbsp;A Convertible accrue dividendsat a rate of 10% per
annum, compounded quarterly, payable quarterly at the Company’s
option in cash or in kind in additionalshares of Series&nbsp;A
Convertible, although the initial dividends payable on the shares
of Series&nbsp;A Convertible issued inSeptember&nbsp;2017, while
accruing from issuance, was payable in December&nbsp;2017. The
Series&nbsp;A Convertible will also beentitled to dividends on an
as-if-converted basis in the same form as any dividends actually
paid on shares of common stock orother securities. The initial
conversion rate is subject to appropriate adjustment in the event
of a stock split, stock dividend,combination, reclassification or
other recapitalization affecting the common stock. During the six
months ended March 31, 2018,the Company issued an additional 11,045
shares of Series A Convertible to settle the related dividends that
are due on a quarterlybasis. The Company recognized a beneficial
conversion charge of $381,664 during the three months ended March
31, 2018, whichrepresents the in-the-money value of the conversion
rate as of the date of issuance.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Concurrent with completing the sale ofSeries A Convertible in
October 2017, the Noteholders exchanged $1,500,000 in aggregate
principal borrowings and $41,507 in accruedinterest for 1,500,000
shares of Series&nbsp;B Convertible. The exchange was accounted for
as an extinguishment of debt. See Note7.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Series&nbsp;B Convertible are non-voting,do not accrue
dividends nor do the shares of Series&nbsp;B Convertible have any
specific rights or preferences, and have a statedvalue of  $1.00
per share and are convertible into 2,112,676 shares of common
stock. The Series&nbsp;B Convertible are notconvertible into common
stock if the holder thereof would beneficially own more than 9.99%
of the common stock, or, if during thefirst six-month period
following the closing of the exchange, 7.50%, but automatically
converts into common stock in part fromtime to time if the holder
beneficially owns below a certain beneficial ownership threshold of
the common stock.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
&nbsp;</p>
<!-- Field: Page; Sequence: 13; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Notes to Unaudited Interim Consolidated
FinancialStatements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Common stock warrants</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
As of March 31, 2018, the Company had the following
warrantsoutstanding to acquire shares of its common stock:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Outstanding</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Exercise<br />
price&nbsp;per<br />
share</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Expiration<br />
date</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2" style="text-align: right">
&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 51%; text-align: left">Series A warrants</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 12%; text-align: right">3,333,333</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">6.60</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 18%; text-align: right">February 18, 2019</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Series B warrants</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,333,333</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">8.50</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right">May 18, 2018</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Common stock warrants issued with
initial public offering</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">817,838</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">0.01</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right">November 11, 2019</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Common stock warrants issued with
senior secured notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,882,001</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">3.00</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: right">December 22, 2021</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Common stock
warrants issued with Series A Convertible</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
16,750,000</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">0.90</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: right; padding-bottom: 1pt">October 31,
2025</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
28,116,505</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>10.&nbsp;&nbsp;&nbsp;Stock-Based Compensation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>2011 Equity Incentive Plan</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company’s 2011 Equity CompensationPlan (the “2011 Plan”)
provided for the Company to sell or issue restricted common stock,
RSUs, performance-based awards(“PSUs”), cash-based awards or to
grant stock options for the purchase of common stock to officers,
employees, consultantsand directors of the Company. The 2011 Plan
was administered by the board of directors or, at the discretion of
the board of directors,by a committee of the board. The number of
shares of common stock reserved for issuance under the 2011 Plan is
851,926. As of March31, 2018, PSUs representing 163,934 shares of
the Company’s common stock were outstanding under the 2011 Plan. In
light ofthe December 2015 adoption of the 2015 Equity Incentive
Plan, (the “2015 Plan”) no future awards under the 2011 Planwill be
granted.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>2015 Equity Incentive Plan</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In December&nbsp;2015, the Company adoptedthe 2015 Plan. The 2015
Plan provides for the grant of stock options, stock appreciation
rights, restricted stock awards, RSU awards,performance stock
awards and other forms of equity compensation to Company employees,
directors and consultants. The maximum numberof shares of common
stock that may be issued under the 2015 Plan is 2,638,101 shares.
As of March 31, 2018, 1,697,339 shares remainedavailable for grant
under the 2015 Plan.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company recorded stock-based compensation(income) expense in
the following expense categories of its statements of operations
for the three and six months ended March 31,2018 and 2017:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Three months ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Six months ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 40%; text-align: left">Research and
development</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">(403,034</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">431,706</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">(84,793</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">817,815</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">General and
administrative</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
102,823</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
1,895,685</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
1,674,402</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
3,973,628</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(300,211</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
2,327,391</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
1,589,609</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
4,791,443</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
<b>Stock options</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
During the six monthsended March 31, 2018, the Company granted a
total of 205,000 stock options to its board of directors and
employees of which20,000 options granted will vest 50% on the third
anniversary of the commencement date and the remaining 50% on the
fourth anniversaryof the commencement date, 60,000 options granted
will vest on the first anniversary of the grant date and 125,000
optionsgranted will vest ratably over three years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<!-- Field: Page; Sequence: 14; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Notes to Unaudited Interim Consolidated
FinancialStatements</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
As of March 31, 2018, optionsto purchase common stock of the
Company outstanding under the 2015 Plan were as follows:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"color: black; font-weight: bold; text-align: center">Weighted</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"color: black; font-weight: bold; text-align: center">Average</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"color: black; font-weight: bold; text-align: center">Weighted</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"color: black; font-weight: bold; text-align: center">
Remaining</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"color: black; font-weight: bold; text-align: center">Number
of</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"color: black; font-weight: bold; text-align: center">Average</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"color: black; font-weight: bold; text-align: center">
Contractual</td>
<td style="color: black; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="color: black; font-weight: bold; padding-bottom: 1pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Shares</td>
<td style="padding-bottom: 1pt; color: black; font-weight: bold">
&nbsp;</td>
<td style="color: black; font-weight: bold; padding-bottom: 1pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Exercise Price</td>
<td style="padding-bottom: 1pt; color: black; font-weight: bold">
&nbsp;</td>
<td style="color: black; font-weight: bold; padding-bottom: 1pt">
&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Term (Years)</td>
<td style="padding-bottom: 1pt; color: black; font-weight: bold">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="color: black">Balance at October&nbsp;1, 2017</td>
<td style="color: black">&nbsp;</td>
<td style="color: black; text-align: left">&nbsp;</td>
<td style="color: black; text-align: right">-</td>
<td style="color: black; text-align: left">&nbsp;</td>
<td style="color: black">&nbsp;</td>
<td style="color: black; text-align: left">$</td>
<td style="color: black; text-align: right">-</td>
<td style="color: black; text-align: left">&nbsp;</td>
<td style="color: black">&nbsp;</td>
<td style="color: black; text-align: left">&nbsp;</td>
<td style="color: black; text-align: right"></td>
<td style="color: black; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 55%; color: black">Granted</td>
<td style="width: 1%; color: black">&nbsp;</td>
<td style="width: 1%; color: black; text-align: left">&nbsp;</td>
<td style="width: 12%; color: black; text-align: right">
205,000</td>
<td style="width: 1%; color: black; text-align: left">&nbsp;</td>
<td style="width: 1%; color: black">&nbsp;</td>
<td style="width: 1%; color: black; text-align: left">&nbsp;</td>
<td style="width: 12%; color: black; text-align: right">1.23</td>
<td style="width: 1%; color: black; text-align: left">&nbsp;</td>
<td style="width: 1%; color: black">&nbsp;</td>
<td style="width: 1%; color: black; text-align: left">&nbsp;</td>
<td style="width: 12%; color: black; text-align: right"></td>
<td style="width: 1%; color: black; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="color: black; padding-bottom: 1pt">
Expired/forfeited/cancelled</td>
<td style="color: black; padding-bottom: 1pt">&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; color: black; text-align: left">
&nbsp;</td>
<td style=
"border-bottom: Black 1pt solid; color: black; text-align: right">
(15,000</td>
<td style="padding-bottom: 1pt; color: black; text-align: left">
)</td>
<td style="color: black; padding-bottom: 1pt">&nbsp;</td>
<td style="color: black; text-align: left">&nbsp;</td>
<td style="color: black; text-align: right">1.32</td>
<td style="padding-bottom: 1pt; color: black; text-align: left">
&nbsp;</td>
<td style="color: black; padding-bottom: 1pt">&nbsp;</td>
<td style="color: black; text-align: left">&nbsp;</td>
<td style="color: black; text-align: right"></td>
<td style="padding-bottom: 1pt; color: black; text-align: left">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="color: black; padding-bottom: 2.5pt">Balance at March
31, 2018</td>
<td style="color: black; padding-bottom: 2.5pt">&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; color: black; text-align: left">
&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; color: black; text-align: right">
190,000</td>
<td style="padding-bottom: 2.5pt; color: black; text-align: left">
&nbsp;</td>
<td style="color: black; padding-bottom: 2.5pt">&nbsp;</td>
<td style="color: black; text-align: left">$</td>
<td style="color: black; text-align: right">1.22</td>
<td style="padding-bottom: 2.5pt; color: black; text-align: left">
&nbsp;</td>
<td style="color: black; padding-bottom: 2.5pt">&nbsp;</td>
<td style="color: black; text-align: left">&nbsp;</td>
<td style="color: black; text-align: right">9.7</td>
<td style="padding-bottom: 2.5pt; color: black; text-align: left">
</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="color: black; text-align: left; padding-bottom: 2.5pt">
Vested and exercisable</td>
<td style="color: black; padding-bottom: 2.5pt">&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; color: black; text-align: left">
&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; color: black; text-align: right">
-</td>
<td style="padding-bottom: 2.5pt; color: black; text-align: left">
&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="color: black; text-align: left; padding-bottom: 2.5pt">
Vested and expected to vest at March 31, 2018</td>
<td style="color: black; padding-bottom: 2.5pt">&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; color: black; text-align: left">
&nbsp;</td>
<td style=
"border-bottom: Black 2.5pt double; color: black; text-align: right">
190,000</td>
<td style="padding-bottom: 2.5pt; color: black; text-align: left">
&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1.22</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">9.7</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The weighted average grant date fair valueof the options awarded to
employees for the six months ended March 31, 2018 was $0.73 per
share. The aggregate intrinsicvalue represents the total amount by
which the fair value of the common stock subject to options exceeds
the exercise price ofthe related options.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
As of March 31, 2018, the aggregate intrinsicvalue of the unvested
options was $0.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The fair value of the options was estimatedon the date of grant
using a Black-Scholes option pricing model with the following
weighted-average assumptions:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">March 31,</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 85%; text-align: left">Risk-free interest
rate</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 12%; text-align: center">2.25%</td>
<td style="width: 1%; text-align: left"></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Expected life</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: center">5.93 &nbsp;years</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Expected volatility</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: center">64%</td>
<td style="text-align: center"></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Expected dividend yield</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: center">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
As of March 31, 2018, there was $112,015 of
unrecognizedcompensation expense that is expected to be recognized
over a weighted-average period of 2.42 years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Performance-based stock units</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company has issued PSUs, which generallyhave a ten year life
from the date of grant and vest 50% after the third anniversary
from issuance and the remaining 50% on thefourth anniversary. The
PSUs are exercisable upon the earlier of (i) a change in control,
(ii) consummation of an initial publicoffering, or (iii) a
corporate valuation in excess of $400 million. Upon exercise, the
PSU holder receives common stock or cashat the Company’s
discretion.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The following table summarizes the activityrelated to PSUs during
the six months ended March 31, 2018:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">Weighted</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">Number</td>
<td style="font-weight: bold">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">Average</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">of</td>
<td style="font-weight: bold">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">Base Price</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
PSUs</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Per Unit</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 70%">Balance at October&nbsp;1, 2017</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 12%; text-align: right">175,530</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">6.30</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1pt">Forfeitures</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(11,596</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt; text-align: right">6.21</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt">Balance at March 31, 2018</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
163,934</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="padding-bottom: 2.5pt; text-align: left">$</td>
<td style="padding-bottom: 2.5pt; text-align: right">6.30</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
As of March 31, 2018, there was $46,066of unamortized expense that
will be recognized over a weighted-average period of 0.69
years.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">
&nbsp;</p>
<!-- Field: Page; Sequence: 15; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Oncobiologics, Inc.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Notes to Unaudited Interim Consolidated
FinancialStatements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Restricted stock units</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The RSUs generally vest over a period of two to four years fromthe
date of grant. The following table summarizes the activity related
to RSUs during the six months ended March 31, 2018:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">Weighted</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">Number</td>
<td style="font-weight: bold">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">Average</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">of</td>
<td style="font-weight: bold">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center">Grant&nbsp;Date</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
RSUs</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Fair&nbsp;Value</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 70%">Balance at October&nbsp;1, 2017</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 12%; text-align: right">939,879</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">18.78</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>Granted</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">20,000</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1.16</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Vested and settled</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(806,514</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">17.51</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1pt">Forfeitures</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(55,592</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt; text-align: right">16.62</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt">Balance at March 31, 2018</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
97,773</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="padding-bottom: 2.5pt; text-align: left">$</td>
<td style="padding-bottom: 2.5pt; text-align: right">22.84</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
As of March 31, 2018, there was $880,559of unamortized expense that
will be recognized over a weighted-average period of 1.40
years.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>11.&nbsp;&nbsp;&nbsp;Subsequent Events</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
On May&nbsp;11, 2018, the Company entered into a purchaseagreement
(the “May 2018 Purchase Agreement”) with GMS Tenshi pursuant to
which the Company agreed to sell to GMSTenshi, and GMS Tenshi
agreed to purchase, in a private placement, $15.0&nbsp;million of
the Company’s common stock andwarrants to acquire that number of
shares of common stock having an aggregate exercise price of
approximately $20.0&nbsp;million,to close in two tranches.&nbsp; On
May&nbsp;14, 2018, the Company closed the sale of the first tranche
of the common stock andwarrants for aggregate cash proceeds of
$7.5&nbsp;million, issuing to GMS Tenshi an aggregate of 6,377,383
shares of its commonstock and warrants to acquire up to 10,256,410
additional shares of its common stock at an exercise price of
$0.975 per share,which warrants have a term of eight years from
their issuance date. Under the May 2018 Purchase Agreement, the
Company and GMSTenshi will close the sale of the remaining
$7.5&nbsp;million of common stock and warrants beginning on
June&nbsp;11, 2018 butno later than September&nbsp;21, 2018,
although, if necessary, GMS Tenshi agreed to acquire that portion
of the second trancheof common stock and warrants no later than
June&nbsp;11, 2018 if necessary for the Company to achieve
compliance with the minimummarket value of listed securities
requirement of the Nasdaq Capital Market.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style="margin: 0">In connection with the May 2018 Purchase
Agreement, the Company and GMS Tenshi amendedthe Investor Rights
Agreement dated September&nbsp;11, 2017, in order to provide GMS
Tenshi certain registration and other rights withrespect to the
shares of common stock to be acquired pursuant to the May 2018
Purchase Agreement and the shares of common stockthat may be
issuable upon exercise of the warrants acquired pursuant to the May
2018 Purchase Agreement.</p>
<p style="margin: 0">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<!-- Field: Page; Sequence: 16; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><a name="a_008" id="a_008"></a>Item&nbsp;2. Management’s
Discussionand Analysis of Financial Condition and Results of
Operations</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>You should read this section in conjunctionwith our unaudited
interim consolidated financial statements and related notes
included in Part I. Item 1 of this report and ouraudited
consolidated financial statements and related notes thereto and
management’s discussion and analysis of financialcondition and
results of operations for the years ended September 30, 2017 and
2016 included in our Annual Report on Form 10-Kfor the year ended
September 30, 2017, filed with the Securities and Exchange
Commission, or SEC, on December 29, 2017, as amendedto
date.</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Forward-Looking Statements</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>This discussion contains forward-lookingstatements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities ExchangeAct of 1934, as amended.
Forward-looking statements are identified by words such as 
“believe,” “may,” “could,”“will,” “estimate,” “continue,” 
“anticipate,” “intend,” “seek,”“plan,” “expect,” “should,” “would,”
“potentially” or the negativeof these terms or similar expressions
in this report. You should read these statements carefully because
they discuss future expectations,contain projections of future
results of operations or financial condition, or state other 
“forward-looking” information.These statements relate to our future
plans, objectives, expectations, intentions and financial
performance and the assumptionsthat underlie these statements.
These forward-looking statements are subject to certain risks and
uncertainties that could causea difference include, but are not
limited to, those discussed under the caption “Risk Factors” in our
Annual Reporton Form 10-K for the year ended September 30, 2017,
filed with the SEC on December 29, 2017, as amended to date, and
elsewherein this report. Forward-looking statements are based on
our management’s current beliefs and assumptions and based on
informationcurrently available to our management. These statements,
like all statements in this report, speak only as of their date,
and weundertake no obligation to update or revise these statements
in light of future developments.</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Overview</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
We are a clinical-stage biopharmaceuticalcompany focused on
identifying, developing, manufacturing and commercializing complex,
technically challenging and commerciallyattractive monoclonal
antibody, or mAb, therapeutics. A mAb is a type of protein that is
produced by a single clone of cells orcell line and made to bind to
a specific substance in the body. Our strategy is to
cost-effectively develop these innovative and/orbiosimilar product
candidates on an accelerated timeline, which is fundamental to our
success and we believe positions us to bea leading biotechnology
company. We have leveraged our team’s biopharmaceutical expertise
to establish fully integrated in-housedevelopment and manufacturing
capabilities, which we refer to as our BioSymphony Platform. We
believe this platform addresses thenumerous complex technical and
regulatory challenges in developing and commercializing mAb
therapeutics and was designed to providesignificant pricing
flexibility to meet the need for clinically important yet
affordable drugs. We have advanced two of our productcandidates
through Phase&nbsp;1 clinical trials and into preparations for
Phase&nbsp;3 clinical trials: ONS-3010, a biosimilarto adalimumab
(Humira<font style="font-size: 10pt">®</font>), and ONS-1045, a
biosimilar to bevacizumab (Avastin<font style=
"font-size: 10pt">®</font>).We plan to advance ONS-3010 and
ONS-1045 into Phase 3 clinical trials upon entering into a license
or co-development agreementwith a partner. Additionally, we are
developing ONS-5010 as an innovative mAb therapeutic that is
expected to enter the clinicin 2018. We continue to develop other
earlier stage therapeutic candidates that we intend to take through
the pre-clinical stagewith the goal of entering into clinical
trials upon securing a development partner for major markets such
as the United Statesand the EU.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
We have made a strategic decision to maximizethe value of our
BioSymphony Platform to assist development stage biopharmaceutical
and biotechnology companies with the developmentand manufacturing
of their product candidates for clinical trials on a contract
basis. We believe that this strategy to leveragethe BioSymphony
Platform and its capabilities will generate funding for our
in-house development programs while we continue todevelop our
pipeline by providing a flexible and cost-effective alternative to
the larger contract manufacturing organizationscurrently serving
this market.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Through March 31, 2018, we have fundedsubstantially all of our
operations through the sale and issuance of $180.3 million in net
proceeds of our equity and debtsecurities. We have also received
$29.0&nbsp;million pursuant to our collaboration and licensing
agreements. In September&nbsp;2017,we closed on the initial sale of
32,628 shares of our newly-created Series&nbsp;A Convertible
Preferred Stock, or the Series&nbsp;AConvertible, to GMS Tenshi
Holdings Pte. Limited, or GMS Tenshi, for $3.3&nbsp;million of
cash, and entered into an investor rightsagreement in connection
therewith. In October&nbsp;2017, following receipt of necessary
stockholder approval, we issued an additional217,372 shares of our
Series&nbsp;A Convertible and warrants to acquire 16,750,000 shares
of our common stock to GMS Tenshi for$21.7&nbsp;million of cash.
Concurrent with such second closing, we also exchanged an aggregate
$1.5&nbsp;million of outstandingsenior secured notes into 1,500,000
shares of our newly-created Series&nbsp;B Convertible Preferred
Stock, or the Series&nbsp;BConvertible.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Additionally, as part of the GMS Tenshitransaction, in September
2017, we entered into a joint development and licensing agreement
for ONS-3010 and ONS-1045 in all emergingmarket territories not
previously licensed to other development partners.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
On May&nbsp;11, 2018, we enteredinto a purchase agreement with GMS
Tenshi pursuant to which we agreed to sell to GMS Tenshi, and GMS
Tenshi agreed topurchase, in a private placement,
$15.0&nbsp;million of our common stock and warrants to acquire that
number of shares ofcommon stock having an aggregate exercise price
of approximately $20.0&nbsp;million, to close in two
tranches.&nbsp; OnMay&nbsp;14, 2018, we closed the sale of the
first tranche of the common stock and warrants for aggregate cash
proceeds of$7.5&nbsp;million, issuing to GMS Tenshi an aggregate of
6,377,383 shares of our common stock and warrants to acquire up
to10,256,410 additional shares of our common stock at an exercise
price of $0.975 per share, which warrants have a term ofeight years
from their issuance date. Under the purchase agreement, we and GMS
Tenshi will close the sale of the remaining$7.5&nbsp;million of
common stock and warrants beginning on June&nbsp;11, 2018 but no
later than September&nbsp;21, 2018,although, if necessary, GMS
Tenshi agreed to acquire that portion of the second tranche of
common stock and warrants no laterthan June&nbsp;11, 2018 if
necessary for us to achieve compliance with the minimum market
value of listedsecurities requirement of the Nasdaq Capital Market.
In connection with the entry into the purchase agreement, we and
GMSTenshi amended the Investor Rights Agreement dated
September&nbsp;11, 2017, in order to provide GMS Tenshi
certainregistration and other rights with respect to the shares of
common stock to be acquired pursuant to the purchase agreementand
the shares of common stock that may be issuable upon exercise of
the warrants acquired pursuant to the purchaseagreement.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<!-- Field: Page; Sequence: 17; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
We have incurred recurring losses and negativecash flows from
operations since inception and have an accumulated deficit at March
31, 2018 of $195.7 million, $13.5&nbsp;millionof senior secured
notes due in December&nbsp;2018 and $4.6&nbsp;million of
indebtedness that is due on demand. We will need toraise
substantial additional capital to fund our planned future
operations, commence clinical trials, receive approval for
andcommercialize ONS-5010, ONS-3010 and ONS-1045 and continue to
develop our other pipeline candidates. We plan to finance our
futureoperations with a combination of proceeds from providing
contract development and manufacturing services on a fee for
service basis,the issuance of equity securities, the issuance of
additional debt, potential collaborations and revenues from
potential futureproduct sales, if any. There are no assurances that
we will be successful in obtaining an adequate level of financing
for the developmentand commercialization of ONS-5010, ONS-3010,
ONS-1045 or any other current or future product candidates. If we
are unable to secureadequate additional funding, our business,
operating results, financial condition and cash flows may be
materially and adverselyaffected. These matters raise substantial
doubt about our ability to continue as a going concern. Our interim
unaudited consolidatedfinancial statements do not include any
adjustments that might be necessary if we are unable to continue as
a going concern.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Our current cash resources of $5.9&nbsp;millionas of March 31, 2018
and the $15.0 million in proceeds received and to be received from
our May 2018 privateplacement of common stock and warrants to GMS
Tenshi, are expected to fund our operations through December
2018,excluding repayment of debt. To provide additional working
capital, we continue to engage in active discussions with globaland
regional pharmaceutical companies for licensing and/or
co-development rights to our late- and early-stage pipeline
productcandidates. If we are not successful in raising additional
capital or entering into one or more licensing and/or
co-developmentrights agreements, we may be required to scale back
our plans and place certain activities on hold.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
We do not have any products approved forsale and we have only
generated revenue from our collaboration agreements. We have
incurred operating losses and negative operatingcash flows since
inception and there is no assurance that we will ever achieve
profitable operations, and if achieved, that profitableoperations
will be sustained. Our net loss for the six months ended March 31,
2018 was $9.5 million. Our net loss for the six monthsended March
31, 2017 was $27.1&nbsp;million. In addition, development
activities, clinical and preclinical testing and
commercializationof our product candidates will require significant
additional financing.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Collaboration and License Agreements</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
From time to time, we enter into collaborationand license
agreements for the research and development, manufacture and/or
commercialization of our products and/or product candidates.These
agreements generally provide for non-refundable upfront license
fees, development and commercial performance milestone
payments,cost sharing, royalty payments and/or profit sharing.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Selexis SA</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In October 2011, we entered into a researchlicense agreement with
Selexis SA, or Selexis, pursuant to which we acquired a
non-exclusive license to conduct research internallyor in
collaboration with third parties to develop recombinant proteins
from mammalian cells created lines using the Selexis
expressiontechnology, or the Selexis Technology. The original
research license had a three-year term, but on October 9, 2014, was
extendedfor an additional three-year term through October 9, 2017,
and then extended for one more year through October 9, 2018. We
maysublicense our rights with Selexis’ prior written consent but
are prohibited from making commercial use of the Selexis
Technologyor the resultant recombinant proteins comprising our
product candidates in humans, or from filing an investigational new
drug,absent a commercial license agreement with Selexis covering
the particular product candidate developed under the research
license.In connection with the entry into the research license, we
paid Selexis an initial fee and agreed to make additional annual
maintenancepayments of the same amount for each of the three years
that the research license agreement term was extended.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Selexis also granted us a non-transferrableoption to obtain a
perpetual, non-exclusive, worldwide commercial license under the
Selexis Technology to manufacture, or havemanufactured, a
recombinant protein produced by a cell line developed using the
Selexis Technology for clinical testing and commercialsale. We
exercised this option in April 2013 and entered into three
commercial license agreements with Selexis for our
ONS-3010,ONS-1045 and ONS-1050 biosimilar candidates. We paid an
upfront licensing fee to Selexis for each commercial license and
also agreedto pay a fixed milestone payment for each licensed
product. In addition, we are required to pay a single-digit royalty
on a finalproduct-by-final product and country-by-country basis,
based on worldwide net sales of such final products by us or any of
ouraffiliates or sub-licensees during the royalty term. At any time
during the term, we have the right to terminate our royalty
paymentobligation by providing written notice to Selexis and paying
Selexis a royalty termination fee.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<!-- Field: Page; Sequence: 18; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>IPCA Laboratories Limited —Humira(ONS-3010), Avastin
(ONS-1045) and Herceptin (ONS-1050)</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In August 2013, we entered into a strategiclicense agreement with
IPCA Laboratories Limited, or IPCA, under which we granted IPCA and
its affiliates a license for the research,development, manufacture,
use or sale of ONS-3010 and, by amendment in May 2014, ONS-1045.
The license is exclusive with respectto India, Sri Lanka and
Myanmar, and non-exclusive with respect to Nepal and Bhutan. Under
the terms of the August 2013 agreement,we received an upfront
payment from IPCA, and are eligible to earn additional regulatory
milestone payments for each of ONS-3010and ONS-1045. In addition,
we are eligible to receive royalties at a low teens percentage rate
of annual net sales of productsby IPCA and its affiliates in the
agreed territory.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In January 2014, we entered into an agreementwith IPCA to assist
IPCA in establishing its research, development and manufacturing
capabilities for mAbs and biologics, including,in part, through
collaborative development, manufacture and commercialization of
ONS-1050 (our Herceptin biosimilar), in the agreedterritory (as
specified below). The agreed territory for ONS-1050 includes the
Republics of India, Sri Lanka, Myanmar, Nepal andBhutan, while the
agreed territory for any product candidates developed independent
of our involvement is global without geographicalrestriction. We
also agreed to assist IPCA with its research and development
program. Under the terms of the January 2014 agreement,we are
eligible to receive development payments and commercialization
fees. In addition, we are eligible to receive royalties fromIPCA at
a mid-single digit rate on annual net sales of ONS-1050
commercialized by IPCA and its affiliates in the agreed
territory.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
As of March 31, 2018, we have receivedan aggregate of $5.0 million
of payments from IPCA under our various agreements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Liomont — Humira (ONS-3010)and Avastin (ONS-1045)</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In June 2014, we entered into a strategiclicense agreement with
Laboratories Liomont, S.A. de C.V., or Liomont, under which we
granted Liomont and its affiliates an exclusive,sublicenseable
license in Mexico for the research, development, manufacture, use
or sale of the ONS-3010 and ONS-1045 biosimilarproduct candidates
in Mexico. Under the terms of the agreement, we received an upfront
payment from Liomont, and we are eligibleto earn milestone payments
for each of ONS-3010 and ONS-1045. In addition, we are eligible to
receive tiered royalties at uppersingle-digit to low teens
percentage rates of annual net sales of products by Liomont and its
affiliates in Mexico. As of March31, 2018, we have received an
aggregate of $3.0 million of upfront and milestone payments from
Liomont.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Huahai — Humira (ONS-3010)and Avastin (ONS-1045)</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In May 2013, we entered into a series ofagreements with Zhejiang
Huahai Pharmaceutical Co., Ltd., or Huahai, to form an alliance for
the purpose of developing and obtainingregulatory approval for, and
commercial launch and marketing of licensed products in an agreed
territory, as described below. Theagreements include a strategic
alliance agreement, which sets out the governance framework for the
relationship, along with a jointparticipation agreement regarding
joint development and commercialization of ONS-3010, and a
co-development and license agreementfor each of ONS-3010 and
ONS-1045. As of March 31, 2018, we have received an aggregate of 
$16.0 million of upfront and milestonepayments from Huahai.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
As contemplated by the strategic allianceagreement, we entered into
a joint participation agreement with Huahai where we agreed to
co-fund the development and share thevalue ownership interest of
ONS-3010 in the United States, Canada, European Union, Japan,
Australia and New Zealand. Under theagreement as amended, we are
responsible for completing a defined “Phase-3 Ready Package” at our
expense, for whichthe portion of the funds received from Huahai to
date under this joint participation agreement was used.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In the event Huahai funds its proportionateshare of development
costs incurred after completion of the “Phase-3 Ready Packages,”
Huahai would be entitled to retainits 51% value ownership, with us
entitled to retain our 49% value ownership, of ONS-3010 in the
agreed territories. Similarly,revenues from commercialization of
ONS-3010 in the agreed countries (including major markets such as
the United States and theEuropean Union, or EU, among others),
would also be shared based on such proportional ownership
interests. In the event that Huahaidoes not fund its proportionate
share of such development costs, the joint participation agreement
provides for a proportionateadjustment to our respective value
ownership interests based on our respective investments in such
development costs, which wouldincrease our value ownership interest
in ONS-3010. Under the joint participation agreement, we could also
be required to form ajoint venture to further develop and
commercialize ONS-3010 with Huahai in the agreed countries, if so
requested by Huahai.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In conjunction with the strategic allianceagreement, we also
entered into a co-development and license agreement with Huahai,
under which we granted Huahai and its affiliatesan exclusive
license, in the territory (as specified below) for the research,
development, manufacture, use or sale of ONS-3010or ONS-1045 in
China, including, the People’s Republic of China, Hong Kong, Macau
and Taiwan. We will each bear our respectivecosts under the
development plans. Huahai agreed to carry out all clinical,
manufacturing and regulatory requirements necessaryfor approval of
the products in the agreed territory. Under the terms of the
agreement, we received an upfront payment from Huahaifor ONS-3010,
and have received regulatory milestone payments for each of
ONS-3010 and ONS-1045.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 19; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><i>&nbsp;</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><i>GMS Tenshi — Humira (ONS-3010) and Avastin
(ONS-1045)</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
On September&nbsp;7, 2017, in connection withthe entry into the GMS
Tenshi purchase agreement for the Series&nbsp;A Convertible and
warrants, we also entered into a joint developmentand license
agreement providing for the license of rights to ONS-3010 and
ONS-1045 in emerging markets, excluding China, Indiaand Mexico,
which superseded and replaced a previous strategic licensing
agreement dated July&nbsp;25, 2017. As of March 31, 2018,we have
received an aggregate of $5.0&nbsp;million of payments from GMS
Tenshi under our joint development and license agreement.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b>Components of our Results of Operations</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>Collaboration Revenue</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
To date, we have derived revenue only fromactivities pursuant to
our collaboration and licensing agreements. We have not generated
any revenue from commercial product sales.Until we begin generating
revenue from our contract development and manufacturing services,
we expect all of our revenue, if any,will be generated from our
collaboration and licensing agreements. If any of our biosimilar
product candidates currently underdevelopment are approved for
commercial sale, we may generate revenue from product sales, or
alternatively, we may choose to selecta collaborator to
commercialize our product candidates.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
The following table sets forth a summary ofrevenue recognized from
our collaboration and licensing agreements for the three and six
months ended March 31, 2018 and 2017,all of which was from the
recognition of deferred revenues under such agreements:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Three months ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Six months ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 48%; text-align: left">IPCA Collaboration</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">65,268</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">65,268</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">130,536</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">130,536</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Liomont Collaboration</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">59,160</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">59,160</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">118,321</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">118,320</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Huahai Collaboration</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">178,712</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">178,712</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">357,423</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">357,425</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">GMS Tenshi
Collaboration</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
468,750</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
937,500</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
771,890</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
303,140</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
1,543,780</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
606,281</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Each of our collaboration and licensing agreementsis considered to
be a multiple-element arrangement for accounting purposes. We
determined that there are two deliverables; specifically,the
license to our biosimilar product candidate and the related
research and development services that we are obligated to
provide.We concluded that these deliverables should be accounted
for as a single unit of accounting. We determined that the upfront
licensepayments received should be deferred and recognized as
revenue on a straight-line basis through the estimated period of
completionof our obligations under the agreement. During the three
months ended December 31, 2016, we revised our estimate of the
periodof completion from December 2019 to December 2021.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>Research and Development Expenses</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Research and development expense consists ofexpenses incurred in
connection with the discovery and development of our product
candidates. We expense research and developmentcosts as incurred.
These expenses include:</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">expenses incurred under agreements
with contract research organizations, or CROs, as well as
investigativesites and consultants that conduct our preclinical
studies and clinical trials;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">manufacturing scale-up expenses and
the cost of acquiring and manufacturing preclinical and
clinicaltrial materials and commercial materials, including
manufacturing validation batches;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">outsourced professional scientific
development services;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">employee-related expenses, which
include salaries, benefits and stock-based compensation;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">payments made under a third-party
assignment agreement, under which we acquired intellectual
property;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">expenses relating to regulatory
activities, including filing fees paid to regulatory agencies;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">laboratory materials and supplies
used to support our research activities; and</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">allocated expenses, utilities and
other facility-related costs.</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<!-- Field: Page; Sequence: 20; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
The successful development of our product candidatesis highly
uncertain. At this time, we cannot reasonably estimate or know the
nature, timing and costs of the efforts that willbe necessary to
complete the remainder of the development of, or when, if ever,
material net cash inflows may commence from anyof our other product
candidates. This uncertainty is due to the numerous risks and
uncertainties associated with the duration andcost of clinical
trials, which vary significantly over the life of a project as a
result of many factors, including:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">the number of clinical sites
included in the trials;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">the length of time required to
enroll suitable patients;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">the number of patients that
ultimately participate in the trials;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">the number of doses patients
receive;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">the duration of patient
follow-up;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">the results of our clinical
trials;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">the establishment of commercial
manufacturing capabilities;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">the receipt of marketing approvals;
and</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-family: Symbol">·</font></td>
<td style="text-align: justify">the commercialization of product
candidates.</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Our expenditures are subject to additionaluncertainties, including
the terms and timing of regulatory approvals. We may never succeed
in achieving regulatory approval forany of our product candidates.
We may obtain unexpected results from our clinical trials. We may
elect to discontinue, delay ormodify clinical trials of some
product candidates or focus on others. A change in the outcome of
any of these variables with respectto the development of a product
candidate could mean a significant change in the costs and timing
associated with the developmentof that product candidate. For
example, if the U.S. Food and Drug Administration, or FDA, or other
regulatory authorities wereto require us to conduct clinical trials
beyond those that we currently anticipate, or if we experience
significant delays in enrollmentin any of our clinical trials, we
could be required to expend significant additional financial
resources and time on the completionof clinical development.
Product commercialization will take several&nbsp;years and millions
of dollars in development costs.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Research and development activities are centralto our business
model. Product candidates in later stages of clinical development
generally have higher development costs thanthose in earlier stages
of clinical development, primarily due to the increased size and
duration of later-stage clinical trials.We expect our research and
development expenses to increase significantly over the next
several&nbsp;years as we increase personnelcosts, including
stock-based compensation, conduct clinical trials and prepare
regulatory filings for our product candidates.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>General and Administrative Expenses</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
General and administrative expenses consistprincipally of salaries
and related costs for personnel in executive, administrative,
finance and legal functions, including stock-basedcompensation,
travel expenses and recruiting expenses. Other general and
administrative expenses include facility related costs,patent
filing and prosecution costs and professional fees for business
development, legal, auditing and tax services and
insurancecosts.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
We anticipate that our general and administrativeexpenses will
increase as a result of increased payroll, expanded infrastructure
and an increase in accounting, consulting, legaland tax-related
services associated with maintaining compliance with stock exchange
listing and SEC requirements, investor relationscosts, and director
and officer insurance premiums associated with being a public
company. We also anticipate that our generaland administrative
expenses will increase in support of our clinical trials as we
expand and progress our development programs.Additionally, if and
when we believe a regulatory approval of a product candidate
appears likely, we anticipate an increasein payroll and expense as
a result of our preparation for commercial operations, particularly
as it relates to the sales and marketingof our product.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>Interest Expense</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Interest expense consists of cash paid andnon-cash interest expense
related to our senior secured notes, former bank loans, notes with
current and former stockholders, equipmentloans and capital lease
and other finance obligations.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>Loss on Extinguishment of Debt</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Loss on extinguishment of debt is attributableto the exchange of
$1.5 million of principal borrowings under our senior secured notes
for shares of Series B Convertible. Theloss represents the excess
fair value of the Series B Convertible that was issued over the
carrying value of the senior securednotes and accrued interest.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<!-- Field: Page; Sequence: 21; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>Change in Fair Value of Warrant Liability</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Warrants to purchase our common stock thathave been issued in
conjunction with our senior secured notes are classified as
liabilities and recorded at fair value. The warrantsare subject to
re-measurement at each balance sheet date and we recognize any
change in fair value in our statements of operationsas other
(income) expense.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>Income Taxes</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
In November 2017, we received approval fromthe New Jersey Economic
Development Authority’s Technology Business Tax Certificate
Transfer Program to sell a portion ofour unused New Jersey net
operating losses, or NOLs, and research and development, or
R&amp;D, tax credits. As a result, we received$3.15 million of cash
from the sale of these NOLs and credits in December 2017. Since
inception, we have not recorded any U.S.federal or state income tax
benefits (excluding the sale of New Jersey state NOLs and research
credits) for the net losses we haveincurred in each year or on our
earned R&amp;D tax credits, due to our uncertainty of realizing a
benefit from those items. Asof September&nbsp;30, 2017, we had
federal and state NOL carryforwards of $131.5&nbsp;million and
$69.6&nbsp;million, respectivelythat will begin to expire in 2030
and 2036, respectively. As of September&nbsp;30, 2017, we had
federal foreign tax credit carryforwardsof $2.9&nbsp;million
available to reduce future tax liabilities, which begin to expire
starting in 2023. As of September&nbsp;30,2017, we also had federal
research and development tax credit carryforwards of 
$0.8&nbsp;million, which begin to expirein 2031.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
In general, under Section&nbsp;382 of the InternalRevenue Code of
1986, as amended, or the Code, a corporation that undergoes an 
“ownership change” is subject to limitationson its ability to
utilize its NOLs to offset future taxable income. We have not
completed a study to assess whether an ownershipchange has occurred
in the past. Our existing NOLs may be subject to limitations
arising from previous ownership changes, and ifwe undergo an
ownership change in connection with or after our initial public
offering, or IPO, our ability to utilize NOLs couldbe further
limited by Section&nbsp;382 of the Code. Future changes in our
stock ownership, some of which are outside of our control,could
result in an ownership change under Section&nbsp;382 of the Code.
Our NOLs are also subject to international regulations,which could
restrict our ability to utilize our NOLs. Furthermore, our ability
to utilize NOLs of companies that we may acquirein the future may
be subject to limitations. There is also a risk that due to
regulatory changes, such as suspensions on the useof NOLs, or other
unforeseen reasons, our existing NOLs could expire or otherwise be
unavailable to offset future income tax liabilities.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>Results of Operations</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><i>Comparison of Three Months Ended March 31, 2018 and
2017</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 13.2pt">
<b><i>&nbsp;</i></b></p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Three months ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Change</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 61%; text-align: left; padding-bottom: 1pt">
Collaboration revenues.</td>
<td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
<td style=
"width: 1%; border-bottom: Black 1pt solid; text-align: left">
$</td>
<td style=
"width: 10%; border-bottom: Black 1pt solid; text-align: right">
771,890</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
<td style=
"width: 1%; border-bottom: Black 1pt solid; text-align: left">
$</td>
<td style=
"width: 10%; border-bottom: Black 1pt solid; text-align: right">
303,140</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
<td style=
"width: 1%; border-bottom: Black 1pt solid; text-align: left">
$</td>
<td style=
"width: 10%; border-bottom: Black 1pt solid; text-align: right">
468,750</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Operating expenses:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt">Research and
development</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,156,386</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">4,116,856</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,039,530</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 9pt">General
and administrative</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,446,505</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
4,024,276</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(1,577,771</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
7,602,891</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
8,141,132</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(538,241</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Loss from operations</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(6,831,001</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(7,837,992</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,006,991</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Interest expense, net</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">920,870</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,243,892</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(323,022</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Change in fair
value of warrant liability</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(211,992</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(1,035,902</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
823,910</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 2.5pt">Net loss</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(7,539,879</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(8,045,982</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
506,103</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>&nbsp;</i></p>
<!-- Field: Page; Sequence: 22; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>&nbsp;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>Collaboration Revenues</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Collaboration revenues increased $0.5 million,to $0.8 million, for
the three months ended March 31, 2018, as compared to $0.3 million
for the three months ended March 31, 2017.The change is due to the
amortization of the upfront payments received in August and
September 2017 under our collaboration arrangementwith GMS
Tenshi.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>&nbsp;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>Research and Development Expenses</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
The following table summarizes our researchand development expenses
by functional area for the three months ended March 31, 2018 and
2017:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Three months ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%; text-align: left">Preclinical and clinical
development</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">2,074,684</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">188,754</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Compensation and related benefits</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,676,419</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,449,646</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Stock-based compensation</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(403,034</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">431,706</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Other research
and development</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
1,808,317</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
1,046,750</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">
Total research and development expenses</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
5,156,386</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
4,116,856</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
The following table summarizes our researchand development expenses
by compound for the three months ended March 31, 2018 and 2017:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Three months ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2" style="text-align: center">
&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2" style="text-align: center">
&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%">ONS-3010</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">53,351</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">-</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>ONS-1045</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">60,429</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">86,610</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>ONS-5010</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,953,850</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Early-stage compounds</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">7,054</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">102,144</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Personnel related and stock-based
compensation</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,273,385</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,881,352</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Other research
and development</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
1,808,317</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
1,046,750</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">
Total research and development expenses</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
5,156,386</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
4,116,856</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Research and development expenses for the threemonths ended March
31, 2018 increased by $1.0 million compared to the three months
ended March 31, 2017. The increase in researchand development
expenses is primarily related to an increase of $1.9 million
resulting from development costs incurred for theONS-5010 program
as we prepare to initiate clinical trials later in 2018. In
addition, we also had an increase of $0.8 millionin other research
and development costs related to the restart of our manufacturing
plant in fiscal 2018, as well as increasesin rent and business
insurance premiums. These increases were offset by decreased
personnel related costs of $1.6 million for thethree months ended
March 31, 2018. The decrease in personnel related costs was due to
a combination of lower salaries and benefitsfrom reduced employee
headcount in March 2018 related to attrition in late 2017 and lower
stock-based compensation due to the relatedforfeitures of equity
awards by departing employees and the completion of the vesting
period of most pre-IPO equity grants in theprior quarter of fiscal
2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>General and Administrative Expenses</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
The following table summarizes our generaland administrative
expenses by type for the three months ended March 31, 2018 and
2017:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Three&nbsp;months&nbsp;ended&nbsp;March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2" style="text-align: center">
&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2" style="text-align: center">
&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%; text-align: left">Professional fees</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">699,503</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">1,022,618</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Compensation and related benefits</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">708,618</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">744,170</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Stock-based compensation</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">102,823</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,895,685</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Facilities, fees
and other related costs</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
935,561</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
361,803</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 9.9pt">
Total general and administrative expenses</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
2,446,505</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
4,024,276</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<!-- Field: Page; Sequence: 23; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
General and administrative expenses for thethree months ended March
31, 2018 decreased by $1.6 million compared to the three months
ended March 31, 2017. The reduction wasprimarily driven by a
reduction in stock-based compensation expense of $1.8 million
related to the completion of the vesting periodof most pre-IPO
equity grants in the prior quarter of fiscal 2018. Professional
fees, including legal fees, also declined by $0.3million as part of
our ongoing cost reduction efforts. These decreases were offset by
a $0.6 million increase in facilities, feesand other related costs
due to increases in rent and business insurance premiums.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>&nbsp;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>Interest Expense</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Interest expense decreased by $0.3 millionfor the three months
ended March 31, 2018 as compared to the three months ended March
31, 2017, primarily due to the conversionof a portion of our senior
secured notes in October 2017.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<i>Change in Fair Value of Warrant Liability</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
During the three months ended March 31, 2018,we recorded income of
$0.2 million related to the decrease in the fair value of our
common stock warrant liability as a resultof a decrease in the
price of our common stock during the period. For the three months
ended March 31, 2017, we recorded incomeof $1.0 million.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><i>Comparison of Six Months Ended March 31, 2018 and
2017</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Six months ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Change</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 61%; text-align: left; padding-bottom: 1pt">
Collaboration revenues</td>
<td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
<td style=
"width: 1%; border-bottom: Black 1pt solid; text-align: left">
$</td>
<td style=
"width: 10%; border-bottom: Black 1pt solid; text-align: right">
1,543,780</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
<td style=
"width: 1%; border-bottom: Black 1pt solid; text-align: left">
$</td>
<td style=
"width: 10%; border-bottom: Black 1pt solid; text-align: right">
606,281</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
<td style=
"width: 1%; border-bottom: Black 1pt solid; text-align: left">
$</td>
<td style=
"width: 10%; border-bottom: Black 1pt solid; text-align: right">
937,499</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Operating expenses:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 0.125in">Research and
development</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,558,788</td>
<td style="text-align: left"></td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">17,347,243</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(11,788,455</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1pt; padding-left: 0.125in">
General and administrative</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
5,995,757</td>
<td style="padding-bottom: 1pt; text-align: left"></td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
8,892,271</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(2,896,514</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
11,554,545</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
26,239,514</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(14,684,969</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Loss from operations</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(10,010,765</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(25,633,233</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">15,622,468</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Interest expense, net</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,638,753</td>
<td style="text-align: left"></td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,733,037</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(94,284</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Loss on extinguishement of debt</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,252,353</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(1,252,353</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Change in fair
value of warrant liability</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(290,775</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(225,819</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(64,956</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Loss before income taxes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(12,611,096</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(27,140,451</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">14,529,355</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Income tax
(benefit) expense</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(3,150,716</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
4,000</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(3,154,716</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 2.5pt">Net loss</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(9,460,380</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(27,144,451</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
17,684,071</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>Collaboration Revenues</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Collaboration revenues increased $0.9 million,to $1.5 million, for
the six months ended March 31, 2018, as compared to $0.6 million
for the three months ended March 31, 2017.The change is due to the
amortization of the upfront payments received in August and
September 2017 under our collaboration arrangementwith GMS
Tenshi.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>&nbsp;</i></p>
<!-- Field: Page; Sequence: 24; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>&nbsp;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>Research and Development Expenses</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The
following table summarizes our research and development expensesby
functional area for the six months ended March 31, 2018 and
2017:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Six months ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%; text-align: left">Preclinical and clinical
development</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">3,001,755</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">9,133,645</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Settlement of clinical development
contract</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(3,228,613</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Compensation and related benefits</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,102,821</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">4,919,255</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Stock-based compensation</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(84,793</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">817,815</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Other research
and development</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,767,618</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,476,528</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total
research and development expenses</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
5,558,788</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
17,347,243</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The
following table summarizes our research and development expensesby
compound for the six months ended March 31, 2018 and 2017:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Six months ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%">ONS-3010</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">551,188</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">5,590,558</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>ONS-1045</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">341,332</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,841,635</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>ONS-5010</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,953,850</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Early-stage compounds</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">155,385</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">701,452</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Settlement of clinical development
contract</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(3,228,613</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Personnel related and stock-based
compensation</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,018,028</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,737,070</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Other research
and development</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,767,618</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
2,476,528</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">
Total research and development expenses</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
5,558,788</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
17,347,243</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Research and development expenses for the sixmonths ended March 31,
2018 decreased by $11.8 million compared to the six months ended
March 31, 2017 due to reductions in pre-clinicaland clinical
development spending, a related contract settlement and lower
personnel related costs. The reduction of $6.1 millionin
pre-clinical and clinical research and development expenses is
directly related to our decision to postpone the initiation ofour
planned Phase 3 clinical trials for ONS-3010 and ONS-1045 until we
secure additional development partners. This resulted ina $7.5
million decrease in costs related to these two programs, which was
partially offset by almost $2.0 million in developmentcosts
incurred related to our new ONS-5010 program as we prepare for
clinical trials in 2018. During the six months ended March31, 2018,
we also terminated an agreement related to ONS-3010 and ONS-1045
and were able to favorably settle amounts previouslyowed under the
contract resulting in a reduction to our accrued research and
development expenses of $3.2 million. Additionally,we experienced a
reduction of $2.7 million in personnel related costs for the six
months ended March 31, 2018 due to a combinationof lower salaries
and benefits from reduced employee headcount in the current period
as a result of attrition in late 2017 andlower stock-based
compensation due to the related forfeitures of equity awards by
departing employees and the completionof the vesting period of most
pre-IPO equity grants in the prior quarter of fiscal 2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<!-- Field: Page; Sequence: 25; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>General and Administrative Expenses</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
The following table summarizes our generaland administrative
expenses by type for the six months ended March 31, 2018 and
2017:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Six Months Ended March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2" style="text-align: center">
&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="2" style="text-align: center">
&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%; text-align: left">Professional fees</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">1,427,523</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">2,199,797</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Compensation and related benefits</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,304,864</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,466,304</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Stock-based compensation</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,674,402</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">3,973,628</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Facilities, fees
and other related costs</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
1,588,968</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
1,252,542</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 2.5pt">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total general and administrative
expenses</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
5,995,757</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
8,892,271</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
General and administrative expenses for the six months ended
March31, 2018 decreased by $2.9 million compared to the six months
ended March 31, 2017. The reduction was primarily a result of a
decreasein stock-based compensation expenses of $2.3 million
related to the completion of the vesting period of most pre-IPO
equity grantsin the prior quarter of fiscal 2018. In addition,
professional fees, including legal fees, declined by $0.8 million
as part ofour ongoing cost reduction efforts.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>&nbsp;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>Interest Expense</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Interest expense decreased by $0.1 millionfor the six months ended
March 31, 2018 as compared to the six months ended March 31,
2017.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<i>Change in Fair Value of Warrant Liability</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
During the six months ended March 31, 2018,we recorded income of
$0.3 million related to the decrease in the fair value of our
common stock warrant liability as a resultof a decrease in the
price of our common stock during the period. For the six months
ended March 31, 2017 we recorded income of$0.2 million.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>Liquidity and Capital Resources</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
We have not generated any revenue from productsales. Since
inception, we have incurred net losses and negative cash flows from
our operations. Through March 31, 2018, we havefunded substantially
all of our operations through the sale and issuance of
$180.3&nbsp;million net proceeds of our equity securities,debt
securities and borrowings under debt facilities. We have also
received an aggregate of $29.0&nbsp;million pursuant to
ourcollaboration and licensing agreements. In September&nbsp;2017,
we closed on the initial sale of 32,628 shares of
Series&nbsp;AConvertible to GMS Tenshi for $3.3&nbsp;million of
cash, and entered into an investor rights agreement and joint
development andlicensing agreement. In October&nbsp;2017, following
receipt of stockholder approval, we issued an additional 217,372
shares ofour Series&nbsp;A Convertible and warrants to acquire an
aggregate of 16,750,000 shares of our common stock to GMS Tenshi
for$21.7&nbsp;million of cash. We also converted $1.5&nbsp;million
aggregate principal amount of our senior secured notes into
1,500,000shares of our Series&nbsp;B Convertible. In November 2017,
we received approval from the New Jersey Economic Development
Authority’sTechnology Business Tax Certificate Transfer Program to
sell a portion of our unused New Jersey net operating losses, or
NOLs,and research and development tax credits. As a result, we
received $3.15 million of cash from the sale of these NOLs and
creditsin December 2017. We will require additional capital to fund
our operations past December&nbsp;2018.Alternatively, we will be
required to scale back our plans and place certain activities on
hold.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
As of March 31, 2018, we had an accumulateddeficit of 
$195.7&nbsp;million and a cash balance of $5.9&nbsp;million. In
addition, we have $13.5&nbsp;million of seniorsecured notes due in
December&nbsp;2018 and $4.6&nbsp;million of indebtedness that is
due on demand. These matters raise substantialdoubt about our
ability to continue as a going concern. Our unaudited interim
consolidated financial statements do not includeany adjustments
related to the recoverability and classification of recorded asset
amounts or the amounts and classification ofliabilities that might
result from the outcome of this uncertainty. We anticipate
incurring additional losses until such time,if ever, that we can
generate significant sales of our product candidates currently in
development or from receiving fees for contractdevelopment and
manufacturing services that we plan to provide for other
biopharmaceutical companies. We will need substantialadditional
financing to fund our operations and to commercially develop our
product candidates. Management is currently evaluatingvarious
strategic opportunities to obtain the required funding for future
operations. These strategies may include, but are notlimited to:
providing contract development and manufacturing services on a fee
for service basis, private placements of equityand/or debt,
payments from potential strategic research and development,
licensing and/or marketing arrangements with
pharmaceuticalcompanies, and public offerings of equity and/or debt
securities. Additionally, we continue to engage in active
discussions withglobal and regional pharmaceutical companies for
licensing and/or co-development rights to our late- and early-stage
pipeline candidates.There can be no assurance that these future
funding efforts will be successful.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 26; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Our future operations are highly dependenton a combination of
factors, including (i)&nbsp;the timely and successful completion of
additional financing discussed above, (ii)our ability to complete
revenue-generating partnerships with pharmaceutical companies,
(iii) the success of our research and development,(iv) the
development of competitive therapies by other biotechnology and
pharmaceutical companies, and, ultimately,
(v)&nbsp;regulatoryapproval and market acceptance of our proposed
future products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><i>&nbsp;</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><i>Cash Flows</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><i>&nbsp;</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The
following table summarizes our cash flows for each of the
periodspresented:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Six&nbsp;months&nbsp;ended&nbsp;March 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td nowrap="nowrap" colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap" colspan="6" style="text-align: center">
&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 74%; text-align: left">Net cash used in operating
activities</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">(16,110,027</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">(9,952,128</td>
<td style="width: 1%; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Net cash used in investing
activities</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(1,350,329</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(191,877</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt">Net cash provided
by financing activities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
20,210,952</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
7,873,167</td>
<td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 2.5pt">Net increase
(decrease) in cash</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
2,750,596</td>
<td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
(2,270,838</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>&nbsp;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>Operating Activities.</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
During the six months ended March 31, 2018,we used
$16.1&nbsp;million of cash in operating activities resulting from
our net loss of $9.5&nbsp;million and the changein our operating
assets and liabilities of $11.6 million. This use of cash was
partially offset by $4.9&nbsp;million of noncashitems such as
non-cash interest expense, stock-based compensation, change in fair
value of warrant liability, loss on extinguishmentof debt and
depreciation and amortization expense. The change in our operating
assets and liabilities was primarily due to paymentsof our
outstanding accounts payable and accrued expenses from September
30, 2017 as well as the prepayment of certain researchand
development expenses and the amortization of our deferred revenues
from collaborations.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
During the six months ended March 31, 2017,we used $10.0 million of
cash in operating activities, primarily resulting from our net loss
of $27.1 million and the net cashprovided from changes in our
operating assets and liabilities of $10.3 million. These uses of
cash in our operating activitieswere offset by $6.9 million of
noncash items such as non-cash interest expense, stock-based
compensation, change in fair valueof warrant liability and
depreciation and amortization expense. The change in our operating
assets and liabilities was primarilydue to increases in accounts
payable related to the timing of vendor payments for research and
development and in deferred revenuesdue to ratable recognition of
upfront payments received under our collaboration arrangements.
These outflows were offset by decreasesin our prepaid expenses and
other current assets, and increases in accrued expenses, and other
liabilities that relate to the timingof vendor payments and the
recognition of research and development expenses.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>Investing Activities.</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
During the six months ended March 31, 2018and 2017, we used cash of
$1.4 million and $0.2 million, respectively, in investing
activities for the purchase of property andequipment.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<i>Financing Activities.</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
During the six months ended March 31, 2018,net cash provided by
financing activities was $20.2 million, primarily attributable to
$20.6 million in net proceeds from our secondclosing of our Series
A Convertible in October 2017. We also had $0.4 million in debt
payments.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
During the six months ended March 31, 2017,net cash provided by
financing activities was $7.9 million, primarily attributable to
$10.0 million in aggregate proceeds fromour senior secured notes
and warrants in December 2016 and January 2017 and $0.8 million
from the sale of common stock and exerciseof warrants, net of
expenses, these inflows were offset by $3.1 million in debt
payments, primarily $2.4 million to repay seniorbank loans in
December 2016.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 27; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b>Off-Balance Sheet Arrangements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We
did not have any off-balance sheet arrangements as of March
31,2018.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>Contractual Obligations and Commitments</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not
applicable.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b>Critical Accounting Policies and SignificantJudgments and
Estimates</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
The Critical Accounting Policies and SignificantJudgments and
Estimates included in our Form 10-K for the fiscal year ended
September 30, 2017, filed with the SEC on December29, 2017, as
amended to date, have not materially changed.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>JOBS Act Accounting Election</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
The JOBS Act, permits an “emerginggrowth company” such as us to
take advantage of an extended transition period to comply with new
or revised accounting standardsapplicable to public companies until
those standards would otherwise apply to private companies. We have
irrevocably elected to“opt out” of this provision and, as a result,
we will comply with new or revised accounting standards when they
arerequired to be adopted by public companies that are not emerging
growth companies.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><a name="a_009" id="a_009"></a>Item 3. Quantitative and
Qualitative Disclosuresabout Market Risk</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Not applicable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>&nbsp;</b></p>
<!-- Field: Page; Sequence: 28; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><a name="a_010" id="a_010"></a>Item 4. Controls and
Procedures</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">
<b>Evaluation of Disclosure Controls and Procedures</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
The term “disclosure controls and procedures,”as defined in Rules
13a-15(e) and 15d-15(e) under the Exchange Act refers to controls
and procedures that are designed to ensurethat information required
to be disclosed by a company in the reports that it files or
submits under the Exchange Act is recorded,processed, summarized
and reported within the time periods specified in the SEC’s rules
and forms. Disclosure controls andprocedures include, without
limitation, controls and procedures designed to ensure that
information required to be disclosed bya company in the reports
that it files or submits under the Exchange Act is accumulated and
communicated to the company’smanagement, including its principal
executive and principal financial officers, or persons performing
similar functions, as appropriateto allow timely decisions
regarding required disclosure. Our management recognizes that any
controls and procedures, no matterhow well designed and operated,
can provide only reasonable assurance of achieving their objectives
and our management necessarilyapplies its judgment in evaluating
the cost-benefit relationship of possible controls and
procedures.&nbsp;Our management, withthe participation of our chief
executive officer and our chief financial officer, evaluated the
effectiveness of our disclosurecontrols and procedures as of the
end of the period covered by this report. Based on that evaluation,
our chief executive officerand our chief financial officer
concluded that our disclosure controls and procedures were
effective, at the reasonable assurancelevel, as of the end of the
period covered by this report.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">
<b>Changes in Internal Control over Financial Reporting</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
There have been no changes in our internalcontrol over financial
reporting that have materially affected, or are reasonably likely
to materially affect, our internal controlover financial reporting
during our second fiscal quarter ended March 31, 2018.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><a name="a_011" id="a_011"></a>Part II. Other
Information</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><a name="a_012" id="a_012"></a>Item&nbsp;1. Legal
Proceedings</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
From time to time, we may become involved inlitigation relating to
claims arising from the ordinary course of business. Our management
believes that there are currently noclaims or actions pending
against us, the ultimate disposition of which would have a material
adverse effect on our results ofoperations, financial condition or
cash flows.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><a name="a_013" id="a_013"></a>Item&nbsp;1A. Risk
Factors</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not
applicable.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><a name="a_014" id="a_014"></a>Item&nbsp;2. Unregistered Sales
of Equity Securities and Useof Proceeds</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b>Unregistered Sales of Equity Securities</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Not applicable.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<b><a name="a_015" id="a_015"></a>Item 3. Defaults Upon Senior
Securities</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
Not applicable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><a name="a_016" id="a_016"></a>Item&nbsp;4. Mine Safety
Disclosures</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not
applicable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><a name="a_017" id="a_017"></a>Item 5. Other Information</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
None.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 29; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b><a name="a_018" id="a_018"></a>Item 6. Exhibits</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b><u>EXHIBIT INDEX</u></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>&nbsp;</b></p>
<table cellspacing="0" cellpadding="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="width: 9%; border-bottom: black 1pt solid">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>Exhibit</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<b>Number</b></p>
</td>
<td style="width: 1%">&nbsp;</td>
<td style=
"width: 90%; border-bottom: black 1pt solid; text-align: center">
<font style="font-size: 10pt"><b>Description</b></font></td>
</tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
<a href=
"http://www.sec.gov/Archives/edgar/data/1649989/000114420418006335/tv485074_ex10-1.htm"
style="-sec-extract: exhibit">10.1</a></p>
</td>
<td>&nbsp;</td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1649989/000114420418006335/tv485074_ex10-1.htm"
style="-sec-extract: exhibit">Sixth Amendment to Lease Agreement by
and between Oncobiologics, Inc. and Cedar Brook 7 Corporate Center
L.P., dated as of February 1, 2018 (incorporated by reference to
Exhibit 10.1 to the Registrant’s current report on Form 8-K filed
with the SEC on February&nbsp;7, 2018).</a></td>
</tr>
<tr style="vertical-align: top">
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1649989/000157104918000082/tv485465_ex10-1.htm"
style="-sec-extract: exhibit">10.2</a></td>
<td>&nbsp;</td>
<td><a href=
"http://www.sec.gov/Archives/edgar/data/1649989/000157104918000082/tv485465_ex10-1.htm"
style="-sec-extract: exhibit">Amendment #2 to Warrant Agreement
dated May 18, 2016 by and between the Registrant and American Stock
Transfer &amp; Trust Company LLC, as Warrant Agent, dated February
9, 2018 (incorporated by reference to Exhibit 10.1 to the
Registrant’s current report on Form 8-K filed with the SEC on
February&nbsp;9, 2018)</a></td>
</tr>
<tr style="vertical-align: top">
<td><a href="tv493343_ex31-1.htm" style=
"-sec-extract: exhibit">31.1</a></td>
<td>&nbsp;</td>
<td><a href="tv493343_ex31-1.htm" style=
"-sec-extract: exhibit">Certification of Principal Executive
Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.</a></td>
</tr>
<tr style="vertical-align: top">
<td><a href="tv493343_ex31-2.htm" style=
"-sec-extract: exhibit">31.2</a></td>
<td>&nbsp;</td>
<td><a href="tv493343_ex31-2.htm" style=
"-sec-extract: exhibit">Certification of Principal Financial
Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.</a></td>
</tr>
<tr style="vertical-align: top">
<td><a href="tv493343_ex32-1.htm" style=
"-sec-extract: exhibit">32.1*</a></td>
<td>&nbsp;</td>
<td><a href="tv493343_ex32-1.htm" style=
"-sec-extract: exhibit">Certifications of Principal Executive
Officer and Principal Financial Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.</a></td>
</tr>
<tr style="vertical-align: top">
<td>101.INS</td>
<td>&nbsp;</td>
<td>XBRL Instance Document</td>
</tr>
<tr style="vertical-align: top">
<td>101.SCH</td>
<td>&nbsp;</td>
<td>XBRL Taxonomy Extension Schema Document</td>
</tr>
<tr style="vertical-align: top">
<td>101.CAL</td>
<td>&nbsp;</td>
<td>XBRL Taxonomy Extension Calculation Linkbase Document</td>
</tr>
<tr style="vertical-align: top">
<td>101.DEF</td>
<td>&nbsp;</td>
<td>XBRL Definition Linkbase Document</td>
</tr>
<tr style="vertical-align: top">
<td>101.LAB</td>
<td>&nbsp;</td>
<td>XBRL Taxonomy Extension Labels Linkbase Document</td>
</tr>
<tr style="vertical-align: top">
<td>101.PRE</td>
<td>&nbsp;</td>
<td>XBRL Taxonomy Extension Presentation Linkbase Document</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<i>* These certifications are being furnishedsolely to accompany
this Quarterly Report pursuant to 18 U.S.C. Section 1350, and are
not being filed for purposes of Section 18of the Securities
Exchange Act of 1934, as amended, and are not to be incorporated by
reference into any filing of the registrant,whether made before or
after the date hereof, regardless of any general incorporation
language in such filing.</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<i>&nbsp;</i></p>
<!-- Field: Page; Sequence: 30; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
<b><a name="a_019" id="a_019"></a>SIGNATURES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
Pursuant to the requirements of the Securities Exchange Act of
1934,the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2"><b>ONCOBIOLOGICS, INC.</b></td>
</tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 5%">Date:</td>
<td style="width: 45%">May 15, 2018</td>
<td style="width: 1%">&nbsp;</td>
<td style="padding-bottom: 1pt; width: 3%">By:</td>
<td style="border-bottom: black 1pt solid; width: 46%">/s/ Lawrence
A. Kenyon</td>
</tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2">Lawrence A. Kenyon</td>
</tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2">Chief Financial Officer and Secretary, (Principal
Accounting and Financial Officer)</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 31; Options: Last -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
</body>
</html>

